case study on chronic kidney disease slideshare

Global case studies for chronic kidney disease/end-stage kidney disease care

• Kidney International Supplements 10(1):e24-e48
• This person is not on ResearchGate, or hasn't claimed this research yet.

• Brigham and Women's Hospital UNiversty of Zurich University of Cape Town

• The University of Tokyo

Abstract and Figures

Discover the world's research

• 25+ million members
• 160+ million publication pages
• 2.3+ billion citations

• Abinet M. Aklilu

• Nafaa S Mohammed
• Dr. Shakir F Tuleab Alaaraji
• Linfang Zhu
• Huaihong Yuan
• BMC Nephrol

• Fred Barker
• Colette Smith

• Ntombifikile Gloria Mtshali
• Ola A. Naser
• Shatha Q . Al-Temimi

• Nada N. Hassan

• Mohd Hafiz Dzarfan Othman

• N.S. Morozova
• Oleg Admakin
• O. L. Morozova
• E.A. Maslikova
• TRANSPLANTATION

• Matthew Koech
• Mark A Hardy

• Aihua Zhang
• Fan Fan Hou

• Naoki Kashihara

• Sadayoshi Ito
• David Harris
• David C.H. Harris

• Fredric O Finkelstein

• Bernard Morton
• Andrew Ready
• Hyung Joon Ahn

• AM J KIDNEY DIS
• Shingo Fukuma

• Linhong Wang
• Recruit researchers
• Join for free
• Login Email Tip: Most researchers use their institutional email address as their ResearchGate login Password Forgot password? Keep me logged in Log in or Continue with Google Welcome back! Please log in. Email · Hint Tip: Most researchers use their institutional email address as their ResearchGate login Password Forgot password? Keep me logged in Log in or Continue with Google No account? Sign up

Subscribe or Renew

Create an E-mail Alert for This Article

Case 34-2020: a 74-year-old man with chronic kidney disease, permissions, information & authors, metrics & citations, continue reading this article.

Select an option below:

Create your account to get 2 free subscriber-only articles each month.

Already have an account, print subscriber, supplementary material, information, published in.

• Autoimmune Disease
• Cardiology General
• Chronic Kidney Disease
• Clinical Medicine General
• Gastroenterology General
• Hematology/Oncology General
• Nephrology General
• Rheumatology General

Affiliations

Export citation.

Select the format you want to export the citation of this publication.

• Yanya Duan,
• Jing Zhuang,
• Rziwanguli Abudula,
• Changrong Zhang,
• Xuefei Tian,
• Hong Jiang,
• Mohammed Tawhari,
• Nourah Al Oudah,
• Yousof Al Zahrani,
• Mansoor Radwi,

View Options

View options, content link.

Copying failed.

PREVIOUS ARTICLE

Next article, create your account for 2 free subscriber-only articles each month. get free access now..

Casts Nephropathy in a Patient with Chronic Kidney Disease

* corresponding author(s):.

We present the case of a patient with a previous diagnosis of chronic kidney disease (CKD) without an established etiological basis. The patient was admitted with criteria for urgent dialysis, prompting the initiation of renal replacement therapy. During hospitalization, there was a significant decrease in hemoglobin (Hb) associated with a positive direct Coombs test, leading to the consideration of autoimmune origin anemia. However, as the haptoglobin levels were normal, a false positive was determined. As part of the approach, flow cytometry was performed, revealing a phenotype compatible with clonal plasma cell neoplasia. A karyotype and renal biopsy were taken, establishing the diagnosis of multiple myeloma (MM) and nephropathy due to monoclonal spikes. A simple X-ray did not show evidence of osteolytic lesions, a definitive clinical manifestation of MM. The patient started treatment and underwent follow-up by nephrology and hematology. Timely diagnosis is imperative, especially in those with a rapid and atypical decline in renal function. It is essential to suspect primary or secondary associated glomerulopathies. In this patient's case, as previous described, in this diagnosis time of prompt treatment is directly proportional to the prognosis of renal function and overall survival.

Renal biopsy; Monoclonal gammopathy; Acute kidney injury, Direct Coombs.

• Lorem ipsum dolor sit amet, adipiscing elitazaa.
• Lorem ipsum dolor sit amet, consectetur adipiscing elitazaa.
• Lorem ipsum dolor sit amet, consectetur elitazaa.
• Lorem ipsum dolor sit, adipiscing elitazaa.

Abbreviations

Hemoglobin (Hb)

Acute kidney injury (AKI)

Multiple myeloma (MM)

Chronic kidney disease (CKD)

Disease-free survival (DFS)

Revised International Staging System for Multiple Myeloma (R-ISS)

Amyloidosis (AL)

Introduction

MM is a malignant clonal disease of plasma cells. In Mexico, it ranks fourth among the most frequent hematologic neoplasms, with an incidence of 1 to 1.5% [1]. MM follows an evolution from an asymptomatic pre-malignant stage known as monoclonal gammopathy of uncertain significance, progressing to indolent MM and finally to symptomatic MM. AKI is one of the main complications of MM, being more frequently observed at diagnosis with an incidence of 16-31%. It is an important predictor of the prognosis of patients with symptomatic MM, especially those requiring dialysis support. The deterioration of renal function and even probable irreversible fibrosis is attributed to the combination of increased concentration and deposition of monoclonal light chains in the serum, which interact with uromodulin (Tamm-Horsfall) in the loop of Henle generating cylinders that obstruct the tubules and the well-known "MM kidney". The definitive diagnosis of cylinder nephropathy is made through renal biopsy, which reports diffuse tubular damage, with the presence of intratubular cylinders of eosinophilic staining, irregular, angled, and with fracture lines in the distal tubules. Regarding the MM approach, bone marrow aspiration and biopsy should be taken, establish the immunophenotype to assess treatment response, protein electrophoresis, and quantification of IgG-A and M immunoglobulins. Treatment consists of an immunomodulatory agent, a proteasome inhibitor in combination with steroids, and recently, a doubling in disease-free survival (DFS) has been observed by adding monoclonal antibodies (Anti-CD38 - Daratumumab) to the regimen [2-3].

It is crucial to promptly undertake a comprehensive approach in every patient with declining renal function, especially in those exhibiting rapidly progressive behavior. The objective is to establish an etiological diagnosis that allows for targeted treatment. In the case of multiple myeloma (MM) and nephropathy due to monoclonal spikes, timely diagnosis can alter the course of the disease, delineating and in some cases, reversing renal damage. The ultimate goal is to enhance overall survival, impact prognosis and quality of life, while also considering the socioeconomic aspects of the disease.

A 56-year-old male with a history of type 2 Diabetes. The current condition began in July 2023 with paraclinical evidence of serum creatinine of 2.6 mg/dL, so treatment with telmisartan was started. Within a month, kidney damage was exacerbated, reaching present creatinine of 26 mg/dL, with a marked decrease in uresis, asthenia, adynamia, oral intolerance, chills and generalized fasciculations. He went to the emergency room of our hospital because he was drowsy and had difficulty breathing. Laboratories were requested where Hb: 9.2 g/dL, BUN: 128 mg/dL, UREA: 273.9 mg/dL, Cr: 23.53 mg/dL, Total proteins: 12.4 g/dL, Albumin: 2.60 g/dL, Globulins: 9.8 g/dl, K: 6.7 mmol/L, Ca: 12.3 mmol/L, P: 12.0 mmol/L and metabolic acidosis with anion GAP. Dialysis therapy and a diagnostic approach for MM were initiated due to clinical and paraclinical suspicion. Radiographs performed without evidence of osteolytic lesions, results were obtained for B2 microglobulin: 17.35, total serum proteins 9.60, gamma 5.56, albumin/globulin ratio 0.32, monoclonal peak 4.01 g/dL, IgG 3699 g/dL. Flow cytometry reports a phenotype compatible with clonal plasma cell neoplasia, abnormal CD28 and CD56 expression, and identification of kappa light chains. The bone marrow aspirate with bone biopsy reported positive CD138, KAPPA, CD56; in the bone marrow karyotype, a clone with 45 chromosomes, loss of chromosome 14 and the normal line was found. In addition, the ultrasound-guided percutaneous renal biopsy reported cast nephropathy, predominantly lambda positive, with marked regenerative changes of the tubular epithelium, focal mesangiosclerosis and interstitial fibrosis with grade III tubular atrophy. It was decided to start treatment with dexamethasone, carfilzomib and daratumumab without obtaining an adequate renal response. During his hospitalization, jaundice was noted with Hb: 5 g/dL, with a sudden drop of 5 mg/dL in a period of approximately 24 hours. This was ruled out as a probable cause of hemorrhage, so a direct Coombs was requested, which was reactive for IgG, hemolytic anemia was ruled out with normal haptoglobin levels (109 g/L), and a false positive secondary to hyperproteinemia was established.

Currently the patient is being monitored by hematology, who will perform a new bone marrow aspiration to determine response to treatment, and by nephrology to continue hemodialysis.

This patient, prior to admission, had a recent diagnosis of CKD managed by a private physician; apparently, the etiological cause was never identified. Within a month, there was a sudden and severe deterioration in renal function, prompting an investigative approach to rule out associated etiologies. In this scenario, primary or secondary glomerulopathies may account for these clinical presentations. MM is classified as a cause of AKI, present in 16-31% of patients at the time of diagnosis.

The approach to a patient with sudden deterioration in renal function requires ruling out causes such as primary and/or secondary glomerulopathies, drug-induced nephritis, and complications inherent to chronic degenerative diseases. In this patient's case, the hypercalcemia and hyperproteinemia upon admission raised suspicion for diagnostic investigation, having ruled out secondary causes (Table 1).

In MM, diagnosis is possible if it meets any of the following criteria:

Table 1 : Diagnostic criteria [4] MM is diagnosed by fulfilling column 1 and/or column 2.

The osteolytic lesions are present in 70% of patients, being evident when there is erosion of the cortex by 30-50% [4], which was not identified in this case, probably due to a lower percentage of erosion. Therefore, current recommendations suggest magnetic resonance imaging or computed tomography. The suspicion of hemolytic anemia arose due to the sudden decrease in hemoglobin, in addition to alterations in other biomarkers. However, it was ultimately ruled out due to normal haptoglobin levels, indicating a false-positive direct Coombs test, a condition likely and commonly described in gammaglobulinemias [5]. 

Based on the previously described findings, this case meets the criteria with a hemoglobin level of 9.2 g/dL, hypercalcemia with 12.3 mmol/L, AKI with a serum creatinine of 23.53 mg/dL, and flow cytometry with a phenotype compatible with clonal plasma cell neoplasia, abnormal expression of CD28 and CD56, and identification of kappa light chains along with the bone marrow aspirate showing CD138, KAPPA, CD56.

Due to the acute deterioration in renal function, a renal biopsy was performed, revealing tubular cast nephropathy. Tubular cast nephropathy is objectively defined as a serum glomerular filtration rate less than 40 ml/min/1.73m2 or serum creatinine >2mg/dl [6], although it is not a mandatory condition, considering that creatinine depends on previous baseline levels, malnutrition, and associated comorbidities. Tubular cast nephropathy is the most common cause of sudden glomerular filtration decrease in MM, therefore, the clinical expression depends on the site of deposition in the nephron [7].

However, there are other forms of morphological alterations at the nephron level that may cause MM, such as monoclonal gammopathy of renal significance with elevated albuminuria due to glomerular involvement, disorganized fibrillar deposition (fibrils with a diameter of 7-12 nm) leading to immunoglobulin λ-related amyloidosis (AL), with deposition at the glomerular basement membrane, explaining the presence of nephrotic syndrome in these patients. Another type of involvement in MM is proliferative glomerulonephritis (mesangioproliferative, membranoproliferative, or endocapillary) with deposition of monoclonal immunoglobulins, resulting in a nephritic syndrome behavior. Finally, there are Type I cryoglobulinemic glomerulonephritis, monoclonal gammopathy associated with C3, and immunotactoid glomerulopathy with variable nephrological expression, with subnephrotic proteinuria and gradual deterioration in renal function. (reference) 

As there is a greater deposition of chains at the capillary, mesangial, tubular, or interstitial level, mechanisms of nuclear factor κB activation have been described, stimulating the transcription of genes, encoding macrophage and monocyte chemotactic proteins, interleukin 6, interleukin 8, transforming growth factor B (TGF-B). If this inflammatory response is not corrected, it will lead to tubulointerstitial fibrosis and subsequently glomerulosclerosis, resulting in a bleak prognosis for renal function and patient survival. 

The renal biopsy of this patient (gold standard) [8] showed deposits of predominantly lambda chains at the tubular level and ruled out light chain involvement at the glomerular level due to the absence of immune complex deposition, absence of arteriolar damage, and no associated morphological pattern, although grade 3 tubulointerstitial fibrosis and glomerular sclerosis were identified, which condition a poor prognosis for residual renal function. 

After diagnosis, it is necessary to classify patients with the Revised International Staging System for Multiple Myeloma (R-ISS), which includes: B2 microglobulin levels, albumin, lactate dehydrogenase, and high-risk chromosomal mutations: del(17p), t(4;14), t(14;16), classifying patients as stage 1, 2, 3 risk with a 5-year survival rate of 77%, 62%, and 47%, respectively. In this patient, although high-risk mutations were not identified, the levels of the other parameters give a 5-year survival rate of 47% [8].

Regarding treatment, according to the Clinical Practice Guidelines in Oncology (NCCN), the initial treatment may vary depending on the patient's eligibility for stem cell transplantation and other clinical factors. It is important to apply the most effective treatment combinations early in the course of the disease to achieve deep and lasting remissions. New therapies focus on overcoming disease refractoriness. According to this, the first-line treatment for newly diagnosed patients eligible for transplantation is with a proteasome inhibitor (bortezomib), an immunomodulator (lenalidomide), and a steroid (dexamethasone) (VTd). The quadruple regimen is reserved for those with aggressive disease, which consists of adding the monoclonal antibody Anti-CD38 (Daratumumab) to the VTd regimen (D-VTd). The addition of daratumumab is supported by the CASSIOPEIA study, in which it was found to be associated with high rates of minimal residual disease negativity and favorable progression-free survival rates versus VTd alone in eligible transplant candidates with newly diagnosed multiple myeloma. Therefore, this quadruple regimen was selected, in our case, lenalidomide was omitted due to severe renal impairment, which is a contraindication for its use. The preference for carfilzomib over bortezomib was made with the support of increased treatment tolerability according to NCCN guidelines. Once a treatment response is achieved, consolidation with transplantation is recommended. The patient remains on hemodialysis with high cut-off (HCO) filters. High-flow hemodialysis (hemodiafiltration) can remove molecules of 10-20 kDa, however, the weight of lambda chains is approximately 45 kDa, so it is necessary to use HCO, which have the ability to remove chains of higher molecular weight [2]. Rapid clearance of light chains can be achieved by intensive hemodialysis using HCO dialyzers and very high protein permeability (Figures 1 & 2). 

Two randomized trials (MYRE and EuLite) evaluated HCO hemodialysis versus hemodiafiltration; in the HCO groups of both studies, dialysis independence rates at 6 months were 60%, considering no previous associated fibrosis. Currently, based on evidence, combining effective chemotherapy with HCO hemodialysis and/or hemodiafiltration remains a relevant therapeutic option in patients with light chain deposition [11].

In the scenario of a patient with acute renal deterioration, it is important to consider associated pathologies beyond chronic degenerative diseases. In this case, a comprehensive approach allowed the identification of MM and tubular cast nephropathy, the most common histological involvement in this pathology. Having tools such as karyotype and renal biopsy allows the identification of risk mutations and therefore the selection of the most appropriate therapeutic strategies, in order to modify the progression of the disease, increase disease-free survival, decrease associated complications, and achieve recovery of dialysis-free renal function.

• Hurtado Monroy R, Mieloma múltiple (2022) A basic review and real world.
• Xing Y, Yan J, Yu Z, Zhao J, Wang Y, et al. (2022) High-cutoff hemodialysis in multiple myeloma patients with acute kidney injury. Front Oncol 12.
• Leung N, Rajkumar SV (2023) Multiple myeloma with acute light chain cast nephropathy. Blood Cancer J 13.
• Cowan AJ, Green DJ, Kwok M, Lee S, Coffey DG, et al. (2022) Diagnosis and management of multiple myeloma: A review: A review. JAMA: The Journal of the American Medical Association 327: 464–477.
• Berentsen S, Barcellini W (2021) Autoimmune Hemolytic Anemias. The New England Journal of Medicine 385: 1407-1417.
• Kumar SK, Callander NS, Baljevic M, Adekola K, Anderson LD, et al. (2022) NCCN guidelines insights: Multiple Myeloma, Featured updates to the NCCN guidelines. J Natl Compr Canc Netw 20: 8-19.
• Palumbo A, Avet-Loiseau H, Oliva S (2015) Revised international staging system for multiple myeloma: a report from International Myeloma Working Group. J Clin Oncol 33: 2863-2869.
• Bidoux F, Leung N, Belmouaz M, Royal V (2021) Management of acute kidney injury in symptomatic multiple myeloma. Kidney International 570-580.

Citation:  Alexis CH, Pineda MR, Moya MM, Dr. Rodriguez AM (2024) Casts Nephropathy in a Patient with Chronic Kidney Disease. J Clin Stud Med Case Rep 11: 249.

Copyright: © 2024  Cabrera-Huerta A, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Clinical Studies Medical Case Reports

Want to create or adapt books like this? Learn more about how Pressbooks supports open publishing practices.

Day 1:  A 62-year old, recently widowed male Hispanic patient, named Mr. Kevin Ulyses Blanco (K. U. B.) was brought in to the emergency department (ED) by his daughter for progressively worsening shortness of breath, fatigue, a lingering non-productive cough, and generalized edema. One month prior, he noticed dyspnea upon exertion, loss of appetite, nausea, vomiting and malaise, which he attributed to the flu. In the emergency department, he appeared anxious and pale, and had a dry yellow tint to the skin. He denied any chest pain, and he could not recall the last time he urinated. He has history of benign prostatic hyperplasia, diabetes mellitus type 2, hypertension, dyslipidemia, and renal insufficiency for the past two years. His ED assessment findings included: 1+ pedal edema, basilar crackles in the lungs bilaterally, and a scant amount of urine according to a bladder scan. His lab results indicated a glomerular filtration rate (GFR) of 12. Based on his subjective and objective symptoms, he was admitted with a diagnosis of progression of chronic kidney disease (CKD) to end-stage renal disease (ESRD). The plan of care was focused on managing his symptoms and consulting with his nephrologist regarding need for hemodialysis.

Day 3:  Mr. K.U.B had an AV graft placed in his forearm to receive dialysis and a dual-lumen hemodialysis catheter for temporary use. His symptoms were worsening despite medical interventions and hemodialysis was needed urgently. The plan was to continue his medications to manage anemia, HTN, diabetes, and renal disease. The nurse identified psychosocial stressors of financial concern and having to live alone with his worsening health condition. With his daughter living far away, he was worried he wouldn’t have support. He stated that he was worried about the financial burden of hemodialysis and struggled with facing the reality of his diagnosis and what his quality of life would be like in the next few years of his life. A recommendation was made for a social worker and psychiatric consult.

Day 8:  By the end of day 8, most of his acute symptoms had been relieved and he was stable enough to be discharged. He had been in contact with case management for his follow up appointment had been made with his primary physician and discharge teaching was given.

• What modifiable factors could Mr. K.U.B. have addressed to slow the progression of his renal disease?
• What collaborative interventions could be used to enhance his care and ensure continuity of care after discharge?
• What affect did uncontrolled hypertension and poor medication compliance have on his disease process?

Nursing Case Studies by and for Student Nurses Copyright © by jaimehannans is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License , except where otherwise noted.

Share This Book

An official website of the United States government

The .gov means it’s official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

The site is secure. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

• Publications
• Account settings

The PMC website is updating on October 15, 2024. Learn More or Try it out now .

• Advanced Search
• Journal List
• Kidney Int Suppl (2011)
• v.10(1); 2020 Mar

Global case studies for chronic kidney disease/end-stage kidney disease care

Chih-wei yang.

1 Kidney Research Center, Department of Nephrology, Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Taoyuan, Taiwan

David C.H. Harris

2 Centre for Transplantation and Renal Research, Westmead Institute for Medical Research, University of Sydney, Sydney, New South Wales, Australia

Valerie A. Luyckx

3 Institute of Biomedical Ethics and the History of Medicine, University of Zurich, Zurich, Switzerland

4 Renal Division, Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts, USA

Masaomi Nangaku

5 Division of Nephrology, The University of Tokyo School of Medicine, Hongo, Japan

Fan Fan Hou

6 State Key Laboratory of Organ Failure Research, National Clinical Research Center for Kidney Disease, Division of Nephrology, Nanfang Hospital, Southern Medical University, Guangzhou, China

Guillermo Garcia Garcia

7 Servicio de Nefrologia, Hospital Civil de Guadalajara Fray Antonio Alcalde, University of Guadalajara Health Sciences Center, Hospital 278, Guadalajara, Jalisco, Mexico

Hasan Abu-Aisha

8 Almughtaribeen University, Khartoum, Sudan

Abdou Niang

9 Department of Nephrology, Dalal Jamm Hospital, Cheikh Anta Diop University Teaching Hospital, Dakar, Senegal

10 Dialysis Unit, CASMU-IAMPP, Montevideo, Uruguay

Sakarn Bunnag

11 Division of Nephrology, Department of Internal Medicine, Rajavithi Hospital, Bangkok, Thailand

Somchai Eiam-Ong

12 Department of Medicine, Chulalongkorn Hospital, Bangkok, Thailand

Kriang Tungsanga

13 Division of Nephrology, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand

14 Bhumirajanagarindra Kidney Institute, Bangkok, Thailand

Marie Richards

15 SEHA Dialysis Services, Abu Dhabi, United Arab Emirates

Nick Richards

Bak leong goh.

16 Department of Nephrology and Clinical Research Centre, Hospital Serdang, Jalan Puchong, Kajang, Selangor, Malaysia

Gavin Dreyer

17 Department of Nephrology, Barts Health NHS Trust, London, UK

18 Centre for Nephrology, University College London, London, UK

Henry Mzingajira

19 Malawi Ministry of Health, Queen Elizabeth Central Hospital, Blantyre, Malawi

Ahmed Twahir

20 Parklands Kidney Centre, Nairobi, Kenya

21 Department of Medicine, The Aga Khan University Hospital, Nairobi, Kenya

Mignon I. McCulloch

22 Paediatric Intensive and Critical Unit, Red Cross War Memorial Children’s Hospital, University of Cape Town, Cape Town, South Africa

23 Division of Nephrology, College of Medicine, Seoul National University, Seoul, Korea

Charlotte Osafo

24 School of Medicine and Dentistry, College of Health Sciences, University of Ghana, Legon, Accra, Ghana

Hsiang-Hao Hsu

Lianne barnieh.

25 Department of Medicine, University of Calgary, Calgary, Alberta, Canada

26 Pan American Health Organization/World Health Organization’s Coordinating Centre in Prevention and Control of Chronic Kidney Disease, University of Calgary, Calgary, Alberta, Canada

Jo-Ann Donner

27 International Society of Nephrology, Brussels, Belgium

Marcello Tonelli

The prevalence of chronic kidney disease and its risk factors is increasing worldwide, and the rapid rise in global need for end-stage kidney disease care is a major challenge for health systems, particularly in low- and middle-income countries. Countries are responding to the challenge of end-stage kidney disease in different ways, with variable provision of the components of a kidney care strategy, including effective prevention, detection, conservative care, kidney transplantation, and an appropriate mix of dialysis modalities. This collection of case studies is from 15 countries from around the world and offers valuable learning examples from a variety of contexts. The variability in approaches may be explained by country differences in burden of disease, available human or financial resources, income status, and cost structures. In addition, cultural considerations, political context, and competing interests from other stakeholders must be considered. Although the approaches taken have often varied substantially, a common theme is the potential benefits of multistakeholder engagement aimed at improving the availability and scope of integrated kidney care.

The prevalence of chronic kidney disease (CKD) and its risk factors is increasing worldwide, and there is a rapid rise in global need for the treatment of end-stage kidney disease (ESKD). The global nephrology community recognizes the need for a plan to address the growing incidence of CKD and a cohesive approach for CKD/ESKD integrated care. 1 This provides a major challenge for health systems, particularly in lower-middle-income countries (LMICs). Because of the growing demand for expensive kidney replacement therapy (KRT; dialysis or kidney transplantation) and in light of the limited resources, ESKD care must be prioritized against the prevention and treatment of CKD, acute kidney injury (AKI), and other noncommunicable diseases (NCDs).

Countries are responding to the challenge of ESKD in different ways, with variable provision of the components of a kidney care strategy (effective prevention, detection, conservative care, kidney transplantation, and an appropriate mix of dialysis modalities) and World Bank classification of economic status. 2 A key goal stated in the article by Harris et al. 1 was to identify a representative selection of country-based case studies showing different levels of development in managing CKD/ESKD care, which offers valuable learning examples. This article illustrates the different approaches that 15 countries have taken toward integrated kidney care ( Table 1 ). Specific areas of approach, in distinct contexts, provide unique experience in CKD, dialysis, and transplantation for ESKD care that are appropriate for each country. Variability in approaches may be explained by country differences in burden of disease, available human or financial resources, and cost structures. In addition, cultural considerations, political context, and competing interests from other stakeholders are confounding factors. This created value to appreciate the similarities and differences of approaches among the unique pathways obtained from each country’s cases.

Table 1

Summary of the CKD/ESKD care study cases

CKD, chronic kidney disease; ESKD, end-stage kidney disease; KRT, kidney replacement therapy; PD, peritoneal dialysis.

Finally, the current approach to kidney disease in many countries is neither sufficient nor sustainable. Thus, this series of case studies demands the urgent attention of governments and policymakers in each country to achieve better integrated CKD/ESKD care.

Integrated CKD/ESKD Care Cases

Taiwan (high-income country): evolution of comprehensive integrated ckd/eskd care.

High prevalent rates of CKD have continued in Taiwan and are reported to be 6.9% for CKD stage 3 to 5, 9.83% for clinically recognized CKD, and 11.9% for CKD stage 1 to 5. However, overall awareness of CKD is low. 3 The major underlying kidney diseases contributing to ESKD are diabetes mellitus (43.2%), chronic glomerulonephritis (25.1%), hypertension (8.3%), and chronic interstitial nephritis (2.8%). 4 The national kidney care program was initiated in response to high rates and has been successfully implemented across Taiwan, resulting in improvements in outcomes for patients along with sustainable cost reductions for the health care system. The pathway and evolution of the CKD/ESKD program in Taiwan may serve as a template in countries where CKD/ESKD is an emerging health care burden ( Table 2 and Appendix 1 ).

Table 2

Evolutionary pathway and road map of CKD/ESKD integrated care in Taiwan

CKD, chronic kidney disease; ESKD, end-stage kidney disease.

To monitor the incidence and burden of ESKD, a national dialysis registry was initiated in 1987 by the Taiwan Society of Nephrology. After this, the Taiwan Society of Nephrology proposed to the Department of Health to make CKD prevention and care a major public health priority. Subsequently, an integrated CKD care program was initiated to promote the screening of high-risk populations (according to the risk factor analysis of epidemiology studies), patient education, and multidisciplinary team care. The CKD care program started in major hospitals in the first phase, then extended to 90 institutes in 2009, and finally rolled out to clinics of general practitioners in 2011. To encourage enrollment in the CKD care program, the Bureau of National Health Insurance reimbursed comprehensive pre-ESKD care for patients with CKD stage 3b to 5 since 2007 and has extended coverage to CKD stage 1 to 3a (early CKD) in 2011. 5 , 6 , 7

These efforts to combat CKD in Taiwan involve collaboration among government, academia and their respective societies, and nongovernmental organizations (NGOs) to enable a multidisciplinary approach that targets not just CKD but also upstream drivers such as diabetes, hypertension, and hyperlipidemia.

Since November 2003, widely used nephrotoxic Chinese herbs containing aristolochic acid were prohibited through public health legislation. This important step also contributed to CKD/ESKD prevention in Taiwan.

Dedicated nephrologists are key to the success of the program, as this group is crucial for performing roles ranging from CKD screening, education, and treatment to involvement and negotiation of public health policy. The CKD committee within the Taiwan Society of Nephrology was the core for the promotion of CKD prevention activities in collaboration with the government—including the Taiwan Kidney Day campaign, which started in 2005.

Strategies for CKD/ESKD care

The strategy and road map for CKD/ESKD care in Taiwan include the following:

• • extending the target population from severe CKD to early stages of CKD as well as commencing kidney health promotion in the general population;
• • integration of CKD as a target of pay-for-performance health care improvement projects, along with diabetes and cardiovascular disease;
• • implementation of early detection and surveillance via national annual physical checkup data for early CKD;
• • early referral to proper care clinics/hospitals;
• • promoting health literacy to the general public; and
• • increased attention to those at highest risk: elderly, multiple diseases, polypharmacy, and so on.

Other factors that have affected the incidence and prevalence of ESKD in Taiwan include universal health coverage (UHC) along with collaboration among government, academia, and NGOs with nephrology societies. Further efforts will be on the prevention and reduction of AKI, outcome monitoring, the promotion of CKD/ESKD shared decision-making, and kidney conservative care. Finally, sustainable quality care of patients with ESKD receiving KRT should be maintained as the ultimate goal.

Outcome measures include the stabilization of the incidence of ESKD in those younger than 75 years, along with lower mortality, better quality of care, less medical costs, better quality of life, and slower rate of progression in patients as demonstrated by findings from the pre-ESKD and early CKD integrated care program 5 , 6 , 7 and diabetes care program. 8 Recent progress of ESKD care has evolved to include more shared decision-making within advance care planning to enable patients and families to choose from various supportive or conservative care options (KRT and withholding/withdrawal of dialysis, where appropriate). The era of CKD care has in parallel progressed to include multidisciplinary care alongside cardiac-kidney-diabetes care with involvement from cardiologists, nephrologists, and endocrinologists. Together these specialists evaluate and educate through dietary management, medical treatment, and surgical intervention, with the goal of reducing mortality and complications in patients with CKD/ESKD. A new concept of personalized care for patients with multimorbidities on dialysis was initiated to treat patients with evidence-based medicine according to the recommended guidelines while also adjusting and modifying for more personalized therapy. This approach has resulted in the stabilization of diabetes mellitus as a cause of ESKD in Taiwan and has also reduced the use of analgesics in patients with ESKD in the year before the initiation of dialysis. 9 The involvement of vascular surgeons in the care of patients on dialysis has also resulted in a reduction of vascular access reconstruction rates. The overall 5-year survival rate of patients on dialysis is currently ∼55.2%, which lies between the rates observed in Japan and Europe. Although the rate of transplantation has been low in Taiwan, the recent promotion of living-related kidney transplantation has increased.

Japan (high-income country): a mature integrated CKD/ESKD care system

Strategies and action plans for kidney disease have been discussed and implemented in collaboration with national and local governments, academic societies, nonprofit organizations, and patient groups in Japan.

Strategies for kidney disease in Japan have focused on early diagnosis of kidney disease by health checkups conducted in schools or workplaces, improvement in CKD care, and dialysis therapy. Dialysis therapy has been covered by health insurance since 1967, and patients requiring maintenance dialysis treatment have been exempted from medical expenses since 1972. Kidney transplantation has been covered by health insurance since 1978, and the Organ Transplant Law of Japan was legislated in 1997. The Ministry of Health, Labour and Welfare promotes various areas of research, such as the kidney failure research team (founded in 1989) and the medical care of chronic kidney failure (published guidelines for dialysis initiation in 1991).

Following the National Kidney Foundation’s Kidney Disease Outcomes Quality Initiative (KDOQI) Clinical Practice Guidelines for Chronic Kidney Disease: Evaluation, Classification, and Stratification of Risk, a CKD initiative subcommittee was launched in the Japanese Society of Nephrology (JSN) in 2004. 10 To raise awareness of CKD and its complications to society and promote its measures on a national scale, the Japan Association of Chronic Kidney Disease Initiative was founded by JSN in association with the Japanese Society for Dialysis Therapy and the Japanese Society for Pediatric Nephrology in 2006. Since 2007, Kidney Disease Measures Study Meetings, with participation from physicians, nurses, public health specialists, local government staff, and representatives of kidney disease patient groups, were held by the Ministry of Health, Labour and Welfare. These meetings resulted in the formation of the national action plan of CKD strategies in 2008: Future Kidney Disease Measures to Be Achieved. The aim of the strategies is to slow progression of kidney dysfunction, prevent the need for KRT, decrease the number of patients with incipient kidney failure, and reduce cardiovascular complications from CKD. Specifically, this action plan called for raising awareness and disseminating knowledge, a medical cooperation system, improvement in medical treatment standards, development of human resources, and promotion of research. The Ministry of Health, Labour and Welfare is currently revising the national action plan for CKD through the second Kidney Disease Measures Study Meeting, discussing a new national action plan to reduce the number of patients on incident dialysis below 35,000 per year by 2028.

Japanese scientific societies, including JSN, Japanese Society for Dialysis Therapy, and Japan Medical Association, developed various guidelines for referral and care of patients with kidney disease between general practitioners and nephrologists.

In 2013, the Ministry of Health, Labour and Welfare developed a formal document targeting CKD within the national health promotion agenda (Basic Direction for Comprehensive Implementation of National Health Promotion). This document included numerical targets to reduce the number of patients on incident dialysis due to diabetic kidney disease by 2022.

Since Japan instituted UHC in 1961, all citizens are covered by some kind of health insurance. The Japan Revitalization Strategy 2013, a growth strategy announced by the Japanese government extending the nation’s “healthy life expectancy,” was set as one of the themes. 11 Programs to develop a new system of preventive care and health management will be promoted through the requirement of all health insurance societies to analyze data such as health insurance claims. This project program called Data Health Plan will use health data to maintain and improve health conditions of its subscribers, including reduction in the incidence of dialysis. Concrete plans are needed to prevent the onset and worsening of CKD from lifestyle-related disease, such as diabetes or hypertension, identified in specific medical checkups ( Figure 1 ) 12 instituted in 2008. These specific medical checkups are mandated by individual health insurance companies according to the guidelines that outline appropriate laboratory tests to be included, standard inquiries, and the selection and stratification of individuals who require further health guidance. JSN is continuing to emphasize collaboration with other domestic and international societies and regulatory agencies. JSN also achieved its goal of collaborating with the International Society of Nephrology (ISN) and the Japanese Diabetes Society. 13

Relationship between the basic concept of Data Health Plan and chronic kidney disease (CKD), Japan. Reproduced with permission from [Proposal to achieve a decline in the number of dialysis initiations due to lifestyle related diseases—early detection and prevention of onset and progression of CKD]. Nihon Jinzo Gakkai Shi. 2016;58:429–475 [in Japanese]. 12 Copyright © 2016 Japanese Society of Nephrology.

The number of kidney transplantation procedures has increased from 749 in 2000 to 1598 in 2011 and remains constant in 2016 with 1648 total transplants (of note, 1471 from living donors, 61 from donors after cardiac death, and 16 from donors after neurological death). As a proportion of the general population, these rates are low compared to other high-income countries. Standardized incidence ratios of dialysis have significantly decreased since 2008 in Japan ( Figure 2 ). 14 However, the total number of patients on incident dialysis was projected to increase from 36,797 in 2015 to 40,360 in 2025 because of the aging population.

Incidence rates of dialysis by sex and age group in Japan, 2005–2015. Reproduced with permission from Wakasugi M, Narita I. Evaluating the impact of CKD initiatives on the incidence of dialysis in Japan. Jpn J Nephrol. 2018;60:41–49. 14 Copyright © 2018 Japanese Society of Nephrology and the Japanese Journal of Nephrology.

China (upper-middle-income country): prevention and treatment of ESKD

China is the largest LMIC and is home to 20% of the world’s population. CKD is common in China and is now the fastest growing cause of death. 15 The government’s current NCD policy, along with major national medical research grants, focuses predominantly on 5 diseases—cardiovascular disease, cancer, diabetes, chronic respiratory disease, and mental illness—notably excluding CKD. There is no national program for the prevention and treatment of CKD or chronic dialysis in China, though Chinese nephrologists have made great efforts to reduce the prevalence of ESKD and improve outcomes in this population, particularly during the last decade.

Understanding CKD and ESKD burden

CKD is a rapidly growing health burden and is a huge health care challenge in China. Epidemiological studies show that the prevalence of CKD in Chinese adults is 10.8%, 15 representing a population of 120 million patients. As of 2017, there were ∼1 million patients with ESKD in China, with only 52% of them having access to KRT. 16 Based on the current average treatment cost, the annual health care expenditure on dialysis in China is ∼US$50 billion.

A recent study, the China Renal Biopsy Series, analyzed 71,151 patients who had a kidney biopsy at 1 of 938 hospitals in 282 cities across China from 2004 to 2014. 17 This analysis found that IgA nephropathy was the most common glomerular disease with a standardized frequency of 28% and the leading cause of progressive CKD in all age groups. Furthermore, the risk of membranous nephropathy has increased by 13% annually during the last decade. The latter could be associated with the increased level of air pollution with particulate matter <2.5 μm in diameter, a health problem faced by many developing countries.

With the rapid growth of the economy and changes in lifestyle, the prevalence of diabetes mellitus is significantly increasing in China. 18 This increase has changed the pattern of CKD in China. Since 2011, the percentage of CKD due to diabetes has exceeded that of glomerulonephritis-induced CKD in hospitalized patients. 19

AKI is an important driver of CKD, and in China, the incidence of AKI is 11.6% in hospitalized adults 20 and 19.6% in children, 21 but the detection rate is only 0.99% in hospitalized patients. 22 In addition to other known risk factors, nephrotoxic herbs are a potential risk factor for AKI in Chinese adults.

Developing population-based prevention approaches for CKD/ESKD according to the risk factor in the Chinese population

Epidemiological studies have shown that folic acid deficiency is prevalent in Chinese hypertensive populations, particularly in rural areas, and is associated with the risk of development of CKD. 23 A recent large-scale, multicenter, randomized controlled trial conducted in 20 rural communities in China evaluated the efficacy of folic acid supplementation in the prevention of kidney function loss in a hypertensive population without previous cardiovascular disease. 24 Compared to treatment with enalapril alone, the addition of low-dose folic acid significantly reduced the risk of kidney function decline. In patients with CKD at study enrollment, folate supplementation reduced the risk of CKD progression by 56%. Folic acid therapy was also found to reduce the risk of a first stroke 25 and new-onset albuminuria in patients with diabetes. 26 Because folate deficiency has been reported in other developing countries, 27 supplementation of folic acid would be considered a kidney-protective approach for hypertensive populations in these regions.

Developing intervention approaches for delaying progression of CKD in China

Once CKD progresses to ESKD, the risk of death and medical costs increase exponentially. Delaying progression of CKD toward ESKD is an important strategy for reducing the burden of ESKD, particularly in LMIC with limited medical resources. The efficacy of renoprotection by angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in patients with CKD has been demonstrated in randomized controlled trials. 28 , 29 Angiotensin-converting enzyme inhibitors can even be administered in patients with CKD stage 4 and delays the onset of ESKD from 3.5 to 7 years. 30 Uptitration of angiotensin-converting enzyme inhibitor or angiotensin receptor blocker dosages against albuminuria confers further benefit on kidney outcomes in patients with nondiabetic CKD and kidney insufficiency. 31 Given the ∼80,000 patients initiating dialysis every year in China, the uptake of these therapies could save US$120 million annually by delaying dialysis by 1 year for each patient.

Promoting home-based KRT in China

The number of patients on peritoneal dialysis (PD) in China rose from 37,942 in 2012 to 55,373 in 2014. 32 China also has the largest variation in PD uptake among regions, ranging from 14% in mainland China to 73% in Hong Kong. 33 The PD-First policy implemented by Hong Kong health authority may contribute to the higher rate of PD uptake. PD has been recommended as a preferred KRT because of its lower cost, reduced requirement for technical support, and less need for trained medical staff. Increasing access to PD could help increase access to KRT for patients with ESKD, particularly in LMIC.

There are still challenges in delivering PD to patients with ESKD living in rural areas with less access to medical care and dialysis. The Flying Angel program is a model developed by a partnership between the Chinese government, medical centers, and the PD industry to overcome the barriers of promoting PD in rural China. 34 This program develops collaboration between central hospitals and community clinics, provides PD training for community medical practitioners, and has a delivery system for PD fluid and materials. This program has increased access to KRT for rural patients with ESKD. 34

The optimal management of home-based PD is critical for reducing the risk of failure and improving outcomes. By implementing a telephone hotline and mobile phone applications, the collaboration between central hospitals and community clinics is strengthened further, facilitating communication between physicians and patients on PD. Home-based management systems, which include mobile phone applications, also provide lifestyle modification guidance for patients and collects information on treatment response from patients. This model of care increases the compliance of patients on PD and decreases the cost associated with hospital and physician visits.

Mexico (upper-middle-income country): moving toward universal access of CKD/ESKD care

Mexico’s health system does not offer UHC for patients with kidney disease. Social security benefits, including universal access to dialysis and kidney transplantation, are available to individuals employed by the private sector or by the government. However, more than half of the population does not have access to social security benefits and cannot afford private health care services. Access to dialysis and kidney transplantation for this population is limited or nonexistent. 35

To reduce health disparities, a constitutional reform was introduced in 1983, recognizing the right of Mexicans to access health insurance. 36 In 1984, legislation on organ and tissue donation and transplantation was passed by the Mexican congress, including the setup of the National Transplantation Registry, to coordinate and facilitate organ procurement and transplantation. In the 1990s, a network of state transplant coordinators and associated organizations were organized throughout the country, as well as a central coordinating center, the National Transplant Center (CENATRA in Spanish). 37

In 2000, a workshop was convened by the Ministry of Health (MOH) to organize a national dialysis registry, with the participation of representatives of all 32 Mexican state health secretariats; members of the Mexican Society of Nephrology, the Mexican Institute for Nephrology Research, the Mexican Board of Nephrology, and Jalisco Dialysis and Transplant Registry; the directors of the Canadian Organ Replacement Registry and the United States Renal Data System. After this, an ad hoc steering committee began a series of meetings at the MOH’s National Directorate of Epidemiology to set up the registry 38 and a number of actions for the prevention and control of CKD were included in Mexico’s National Health Plan 2001–2006. 39 Among them was the implementation of early screening and treatment of CKD along with a national dialysis registry.

In 2003, a structural reform of the Mexican health system increased financial protection of its citizens by offering publicly subsidized health insurance to more than half of the population not covered by social security. The center of the reform was the creation of Seguro Popular (Popular Health Insurance), 40 which divides personal health services into essential packages of interventions financed by the Fund for Protection against Catastrophic Health Expenditures (FPGC). 41 The law came into effect on January 1, 2004, and dialysis and organ transplantation were among the 7 high-cost interventions included in the FPGC. In 2010, the MOH set up the Strategic Health Services Network Against Chronic Kidney Disease, emphasizing the need for early detection and treatment of CKD. 42

In 2015, the Mexican Health Foundation (FUNSALUD in Spanish) began organizing a series of meetings with representatives from Mexico’s health systems and members of the Mexican nephrology societies to reinitiate the setup of the dialysis registry, which had been abandoned by Mexican health authorities. After the ISN Global Kidney Policy Forum held at the ISN World Congress of Nephrology 2017 in Mexico City, the MOH implemented the pilot testing of the National Registry of Chronic Kidney Disease (RENERC in Spanish) as part of the nation’s health information system.

Thirty-five years after the constitutional reform of 1983, universal access to kidney care is yet to be realized. Since the implementation of Seguro Popular, the proportion of the population with some type of public health insurance has increased from 41% in 2002 to 81% in 2015 43 and the number of high-cost interventions included in the FPGC has increased from 7 to 68. However, Seguro Popular still does not pay for dialysis. As a result, the marked disparities between the insured and uninsured populations with access to KRT persist. By 2015, the incidence and prevalence of patients receiving treatment for ESKD with social security were 281 and 1357 per million population (pmp), respectively; however, 130 patients pmp on incident dialysis and 200 patients pmp on prevalent dialysis remained uninsured. 35

The introduction of legislation on organ donation and transplantation in 1984 resulted in a significant increase in kidney transplantation rates, from 1.57 pmp in 1984 to 22.8 pmp in 2015. However, this success is not observed in the population without social security. Because Seguro Popular still does not cover the cost of kidney transplantation and immunosuppressive drugs, transplantation rates remain significantly lower in patients without social security. 35

Eight years after the setup of the Strategic Health Services Network Against Chronic Kidney Disease, strategies to prevent CKD are yet to become part of the nation’s NCD health policies. CKD screening is low or nonexistent across Mexico. Furthermore, uninsured patients with predialysis CKD are often denied access to treatment by Seguro Popular once identified as having kidney disease. 35 Therefore, the opportunity to intervene to delay the progression of CKD is lost.

Finally, the dialysis registry is currently under pilot testing with the participation of several dialysis centers. The sustainability and nationwide expansion of the registry are yet to be seen.

Sudan (lower-middle-income country): evolution of strategies for CKD/ESKD care

During the 1970s, a Sudanese patient was treated in London, UK, for kidney failure by hemodialysis (HD). As he decided to continue his treatment under the care of medical staff of the University Hospital of Khartoum, his HD machine was the basis for the first dialysis unit in Khartoum.

Around the same time, a young surgeon by the name of Omar Beliel was sent by the University Hospital of Khartoum to train in England to be a neurosurgeon. While in the United Kingdom, he had kidney failure and eventually he received a kidney donated by his brother. Dr. Beliel later wrote an autobiography titled Two Lives: Death Odyssey of a Transplant Surgeon , 44 in which he describes how kidney transplantation gave him a “second life.” He subsequently shifted his training from neurosurgery to transplant surgery and performed the first kidney transplantation procedure in Africa from a living-related donor in 1974. By the mid-1970s, HD, intermittent PD through the use of hard catheters, and living-related kidney transplantation were established services at the University Hospital of Khartoum. However, these services were limited because of resources and the University Hospital remained mostly an academic and teaching facility.

The 1980s saw an expansion in dialysis services to benefit more patients, which was supported by the Ministry of Finance. It was soon evident that these services were costly and further expansion was unlikely to be feasible.

In 1994, the government called for Expert Opinion Conferences on How-Best-to-Do (HBTD) the civil services. The conferences called on scholars and experts in health, education, economy, and other areas to discuss reform of these issues and make recommendations to be executed by the government. A final recommendation in the area of health was to establish the National Centers of Health Care for 5 key areas: kidney disease, heart disease, oncology, gastroenterology and hepatology, and neurosciences. These national centers were required to plan for health care in their respective areas, along with suggestions and the means for successfully operating across the country. Thus, the National Center for Kidney Diseases and Surgery was established in 1995 and has been responsible for CKD/ESKD care across Sudan for the last 2 decades.

The National Medical Supplies Fund was established hand in hand with the National Centers of Health Care. The main objective was to procure and justly distribute medicines nationwide at the lowest cost. An important issue that resulted from the National Medical Supplies Fund policies was the need to have a national regulation for life-saving medicines (LSM), medicines that should be available to all citizens free of charge. After many discussions, it was agreed that the treatment of ESKD was to be considered a lifesaving issue and therefore both dialysis and kidney transplantation would be covered by the LSM bill. Thanks to this huge step forward, the development of both CKD services as preventive measures and ESKD therapy would be managed under the umbrella of the National Center for Kidney Diseases and Surgery.

Another important contribution to the success of managing CKD/ESKD in Sudan is the National Zakat Fund (NZF), which was established in the 1990s. Zakat is an Islamic concept where Muslims with the financial means are required to contribute 2.5% of their annual income as charity. The current government decided, for the first time, to create an organized institution to then use these funds in an orderly fashion. As the activities of the fund are regularly published, it became a trustworthy organization and most individuals who pay zakat prefer NZF to find suitable recipients of the aid. Religious scholars agreed that treatment of ESKD through dialysis and transplantation would be eligible to be supported by NZF.

In 2005, the National Medical Supplies Fund accepted continuous ambulatory PD as a viable option for treatment of ESKD, particularly for children and young patients. It has since become an option for ESKD management, albeit on a limited scale.

Using funds obtained from the LSM bill and NZF, the National Center for Kidney Diseases and Surgery is able to meet the requirements of providing CKD/ESKD care for citizens in Sudan.

Dialysis facilities and modalities

Sudan is the second largest country in Africa, with a total population of ∼38 million. Nearly all cities and large towns have governmental HD centers to care for patients with ESKD. Currently, the total number of HD centers is 72. There are 7200 patients currently on dialysis; 97% of these are on HD. 45 HD is based on twice weekly sessions for stable patients. The reason for this suboptimal dialysis schedule is to accommodate as many patients with EKSD as possible under the free-of-charge scheme of the national HD system. A recent survey showed that the 1-year survival of patients on twice weekly HD was 83%. 46 Patients who had functioning arteriovenous fistulas did significantly better than those who were dialyzed via cuffed or noncuffed central venous catheters. 46 Availability of continuous ambulatory PD is still limited to the greater Khartoum state. Although only 3% of patients on dialysis are on continuous ambulatory PD, the outcome and quality of life figures are rewarding. If PD fluid could be manufactured locally, ideally more patients on PD could be accommodated.

Kidney transplantation

The kidney transplant activities in Sudan over the last 5 years are increasing. Kidneys are transplanted exclusively from living-related donors. About 80% of the cost of the transplant is covered by either the LSM bill or NZF. All patients (irrespective of where the transplant was done) receive immunosuppressive drugs free of charge.

In summary, the most important milestones in developing a strategy for care for patients with CKD/ESKD in Sudan are as follows:

• • The call by the government in 1994 for national conferences to give advice on how best to do reforms across the country. This resulted in the birth of the National Center for Kidney Diseases and Surgery, which plans and supervises kidney care nationwide.
• • The introduction of the LSM bill was a novel resolution that made it possible to view CKD/ESKD care as a lifesaving issue, using funds to cover almost all citizens free of charge.
• • The Islamic system of zakat that requires eligible Muslims to voluntarily pay 2.5% of their annual income to support the poor or programs designed to help the poor. The addition of CKD/ESKD care to be covered by this fund has helped immensely.

Senegal (lower-middle-income country): fundamental development of CKD/ESKD care

Senegal is a country on the western tip of Africa, with a population of 15 million, and is one of the poorest countries in the world. Nephrology was unknown in Senegal until the return of the first Senegalese nephrologist after the conclusion of his training in France. Over time, a dedicated nephrology curriculum for undergraduate medical students along with HD and kidney biopsy practices has been introduced. Until 2010, however, there were only 2 HD centers in each of the public and private health sectors, dialysis costs were paid out of pocket by patients without health coverage, and there were only 3 nephrologists in the country.

Epidemiology

The prevalence of CKD in Senegal is estimated at 4.9%. 47 The main cause of CKD is hypertension, followed by chronic glomerulonephritis (especially primary focal segmental glomerulosclerosis), diabetes, and the use of traditional nephrotoxic drugs. The World Health Organization STEPwise survey found the prevalence of hypertension and diabetes in the general Senegalese adult population aged 45 to 49 years to be 25% and 5.4%, respectively. Advocacy and increased awareness among political authorities has made it possible to set up an NCD office at the MOH with a focal point on nephrology for the management of kidney disease. UHC was introduced in 2014, which provides free dialysis for Senegalese patients, but with limited availability. The government provides all dialysis supplies and a bundled payment of 10.000 FRFA (US$20) for each dialysis session at public dialysis centers. Patients, when dialysis slots are not available, are registered on the first come, first serve waiting list. In the meantime, to survive, patients must pay out of pocket to receive dialysis in the private sector.

Kidney care

A national and international nephrology referral service has been developed at the largest university hospital in Senegal. An average of 200 kidney biopsies are done each year, with samples processed and read on site. HD began at the largest public HD center with 25 stations, and HD services grew from 2 HD centers in 2010 to 20 centers all across Senegal. In 2004, the first PD center was established for the management of acute and chronic kidney failure in children and adults using continuous ambulatory PD and automated PD. 48 The costs of dialysis were first fully and then partially borne by the patient until 2012. Since 2012, dialysis costs, with the exception of epoetins and laboratory tests, are fully covered by the government in the public sector and partly covered in the private sector. In the public sector, dialysis supplies are obtained through the National Pharmacy Supply, through 2-year international tenders, permitting regular renegotiations. Kidney transplantation has not yet been done in Senegal. However, a working group with the support of experts drafted texts and laws governing organ transplantation, which passed a National Assembly vote on November 27, 2015. A presidential decree establishing the National Council for Organ Transplantation is on standby.

Training and education in nephrology

A nephrology school was opened in 2005 in Dakar to fill the gap of nephrologists in the sub-Saharan Africa region as no single country had more than 5 nephrologists, half the countries had no nephrologists, and Senegal had only 3 nephrologists. Between 2005 and 2017, by combining internal medicine and nephrology, the school trained 104 nephrologists from 21 African countries in a 4-year curriculum (including 2 semesters in France). A 2-year curriculum for nephrology nurses was introduced in 2008 and has trained 90 senior nephrology nurses from 7 African countries. In collaboration with the ISN, 3 training workshops on AKI, CKD, and PD have been organized with >400 participants per workshop to meet continuing medical education goals. 49

A working group with diverse experts (doctors, biologists, surgeons, pharmacists, and administrative staff) has been set up by the MOH to achieve an integrated CDK/ESKD care strategic plan. This strategy will enhance awareness and prevention, propose ways to reduce the growing number of patients on dialysis waiting lists, and extend PD to rural areas as it costs less than HD and will allow more patients with ESKD to be treated with dialysis. The annual cost per patient is US$13,650 for PD compared with US$18,000 for HD. 50 Training standards for health care workers must be developed in conjunction with nephrologists. The National Council for Organ Transplantation will be established, and the support of foreign partners will be needed for the accreditation of the initiation of living-related kidney transplantation.

An integrated CDK/ESKD care strategic plan was developed in 2019. The number of patients with CKD on dialysis has grown from 50 in 2010 to >800 currently; this number was doubled in 2019 with the opening of 10 new HD centers across the country. Two new PD centers were opened in 2019. This expanded the treatment of 60 patients with CKD and 20 patients with AKI at the current single center to the treatment of >150 patients with CKD and 50 patients with AKI. From 3 nephrologists in 2008, the country currently has 27 nephrologists and 128 nurses with specialization in nephrology; the goal is to train 5 additional nephrologists and 10 additional specialized nurses per year. The establishment of the National Council for Organ Transplantation will set the rules and criteria for accreditation, enabling the first successful kidney transplantation in Senegal in 2019.

CKD Strategy Cases

Uruguay (high-income country): prevention and treatment of ckd.

Uruguay, a developing country in South America with 3.44 million inhabitants, was classified as a non–Organisation for Economic Co-operation and Development high-income country by the World Bank in the last decade. In recent years, there has been a sustained growth in the aging of the population, and life expectancy at birth has increased to 77 years (73 years for men and 81 years for women). A National Integrated Health System (SNIS in Spanish) was launched in 2008 to provide UHC to the entire population. The total expenditure on health per capita in 2016 was ∼US$1800, which represents 8.6% of the nation’s gross domestic product. 51

The SNIS is funded by contributions from employers, employees, retirees, and tax revenues that go to the National Health Fund (FONASA in Spanish) and the National Fund of Resources (FNR in Spanish) ( Figure 3 ). 52 The FNR is a public nongovernmental agency, created by law in 1980 with the purpose of providing funds for highly specialized medical procedures, such as dialysis and transplantation, on the basis of approved protocols. This fund accounts for ∼10% of all public expenditures on health; expenses related to dialysis account for ∼27% of the entire fund.

National Integrated Health System (SNIS in Spanish) financial sources in Uruguay. Reproduced with permission from Ministerio de Salud Pública. La Construcción del Sistema Nacional Integrado de Salud. 2005–2009. Available at: http://www.paho.org/hq/dmdocuments/2010/construccion_sist_nac_integrado_salud_2005-2009-uruguay.pdf . Accessed March 18, 2018. 52

Action and strategies for CKD/ESKD care

UHC of patients receiving KRT has been available since 1981, with the financial support of the FNR. Data on these patients are collected by the Uruguayan Dialysis Registry.

In April 2004, representatives from the Uruguayan and Latin-American societies of nephrology, the Uruguayan Department of Health, and the FNR signed the Declaration of Montevideo with the aim of enhancing CKD care and recommended an Advisory Committee on Renal Healthcare to develop a National Renal Healthcare Program. Six months later, a pilot program was launched that included (i) education programs on kidney health care, including information on a healthy lifestyle, in the general population, with the aim to reduce cardiovascular and kidney risk factors; (ii) increased accessibility to kidney health care at the primary care level; (iii) promotion of early diagnosis of CKD in the population at risk; (iv) enhanced care given to patients at all stages of CKD; and (v) prevention of cardiovascular morbidity and mortality, as they are high in the target population. 53 , 54

The methodology for developing and spreading the National Renal Healthcare Program included several advances: (i) the development of clinical guidelines for identification, 55 evaluation, and management of patients with CKD at the primary care level; (ii) the creation of kidney care teams (including a nephrologist, a dietitian, and a nurse) to work in primary care centers to treat patients referred to them by primary care practitioners; (iii) the management of patients with CKD stage 1 to 3 directly by the laboratory; and (iv) patients with CKD stage 4 and 5 were referred to a CKD advanced clinic, staffed by a formal multidisciplinary team including nephrologists, dietitians, nurses, psychiatrists, vascular surgeons, and social workers.

An online CKD registry housed at the FNR records data on patients with estimated glomerular filtration rate (eGFR) < 60 ml/min per 1.73 m 2 and persistent albuminuria >300 mg/d (or >30 mg/d in patients with diabetes) and features a centralized alarm system to minimize failure to follow-up. 56 Although the National Renal Healthcare Program is not mandatory for every health care provider, the feasibility of this is being studied. 57

Since 2009, testing for CKD in high-risk populations (case finding) has been incorporated into the mandatory health checkups of the working population via a decree of the Department of Health. Evaluation includes urine examination and serum creatinine tests in diabetic and hypertensive individuals. 58

Not all Latin American countries provide the same level of CKD care, which is why the Latin-American Society of Nephrology and Hypertension (SLANH in Spanish) and the Pan American Health Organization declared that all countries should improve CKD care and increase coverage of dialysis treatment. Together, through Pan American Health Organization’s virtual space, they launched an online course (in Spanish and Portuguese) on CKD prevention and care in July 2016, aimed at primary care practitioners throughout Latin America. 59

Uruguayan Dialysis Registry

Data from the Uruguayan Dialysis Registry found that diabetic and hypertensive diseases are the most common causes of ESKD. 60 The prevalence of ESKD was 756 patients pmp, with 90% on HD and 10% on PD in December 2014; the prevalence of ESKD is 1031 pmp when patients with a functioning kidney allograft are included.

CKD registry

The target population and the variables included in the registry have already been described elsewhere. 61 Between October 1 and December 31, 2017, 20,879 patients were recorded; the mean age was 66 years, and 47.6% were female. The most frequent causes of CKD were vascular nephropathy (40.8%), diabetic nephropathy (19.1%), obstructive nephropathy (7.9%), and primary glomerulonephritis (4.8%). The most frequent risk factors for kidney disease were hypertension (86.9%), dyslipidemia (54.2%), diabetes (37.3%), and obesity (37.7%). Most patients were referred to a nephrologist at later stages (CKD stage 3 or greater). 62

Every year, the Advisory Committee on Renal Healthcare carries out an evaluation that assesses the quality of care at the primary level, the achievement of therapeutic goals under nephrology care, the rate of progression of CKD, and the mortality due to ESKD. There has been a sustained increase in blood pressure control care since 2005, with the proportion of patients with systolic blood pressure <140 mm Hg and diastolic blood pressure <90 mm Hg rising from 36.5% to 63.9% and from 58.5% to 86.5%, respectively. 63

Table 3 highlights some indicators of kidney care in Uruguay. 64 More than 50% of patients are stabilized with an eGFR loss of <1 ml/min per 1.73 m 2 per year, and 79% of patients with diabetes and albuminuria are taking renin-angiotensin system blockade (despite heterogeneity between groups, ranging from 54% to 96%). The risk of new cardiovascular events was related to previous cardiovascular disease, diabetes, male sex, and increased age and albuminuria and had a U-shaped curve for systolic blood pressure. 65 Other than well-known risk factors such as albuminuria and blood pressure, acidosis was related to greater increase in creatinine. 66 Finally, there is evidence that predialysis CKD care may improve outcomes once patients are established on dialysis in Uruguay. 67

Table 3

Achievement of quality of care indicators under nephrology care in Uruguay (National Renal Healthcare Program 2004–2016)

eGFR, estimated glomerular filtration rate; LDL, low-density lipoprotein; RAS, renin-angiotensin system.

Since 1981 in Uruguay, there is UHC for dialysis. A CKD screening and prevention program was launched in 2004. Today, these are being incorporated into mandatory health programs, with the aim of making them universal throughout the country. There has been improvement in the quality of care as well as a reduction in CKD progression; the potential benefits of predialysis CKD care seem to extend even to patients who eventually have kidney failure. CKD care requires the commitment of the nephrology community and the national authorities. The former provides guidelines for systematic CKD detection and follow-up, while the latter sets the framework for health care providers and ensures the provision of UHC for treatment from the early stages of CKD to dialysis and kidney transplantation.

Thailand (upper-middle-income country): unique CKD prevention program

The prevalence of CKD stage 3 and 4 in Thailand is 9.3% for those older than 18 years, representing 4.8 million people, with a further 4.6 million people with CKD stage 1 and 2. 68 Diabetes mellitus and hypertension are the main causes of CKD. 69 The Ministry of Public Health has divided the country into 12 health care regions (excluding the Bangkok metropolitan area), with each region consisting of 4 to 8 provinces covering a population of ∼5 million. Within each province, there are between 6 and 30 districts, each with their own district hospital. Within each district, there are a further 5 to 10 subdistrict health offices. A district hospital usually comprises general practitioners, nurses, pharmacists, a physical therapist, and, in larger hospitals, a nutritionist. At each subdistrict health office, there are 1 to 2 public health officers and 1 to 2 community nurses, caring for anywhere between 3000 and 5000 inhabitants. Community nurses are responsible for basic drug prescription, on behalf of the district hospital, and for treating common ailments. Moreover, there are village health volunteers, grassroots personnel, who provide a connection between villagers and health personnel and cover public health issues at the village level. Basic health care programs in Thailand are implemented through this infrastructure. Across Thailand, there are ∼10,000 subdistrict health offices and >1 million village health volunteers. 70

Diabetes mellitus and hypertension are the 2 most common NCDs in rural areas. To cope with these problems, general practitioners, diabetes/hypertension case manager nurses, and multidisciplinary care teams work together at the district hospital level. Community nurses and village health volunteers are also responsible for medication refills for stable patients and facilitate patients’ self-care and any necessary lifestyle modifications. Key performance indicators from all public hospitals are transferred to the Health Data Center of the Ministry of Public Health. Table 4 illustrates a set of key performance indicators of diabetes and hypertension. 71

Table 4

Key performance indicators of diabetes mellitus and hypertension reportable to the Ministry of Public Health, Thailand

HbA 1c , hemoglobin A 1c .

It is challenging to use the limited resources available in the country to delay the progression of CKD on a national scale. Community nurses and village health volunteers, who are more present in the community, can be trained to decrease the reliance on multidisciplinary care teams who are present only in hospitals. This is a paradigm shift from hospital-based to a joint hospital-community–based approach.

To test this concept of care, a pilot project was launched a few years ago in Kamphaeng Phet Province, 400 km north of Bangkok. In brief, this study took place at 2 districts within the province. 72 In district hospital A (control), there was no multidisciplinary care team available and patients were cared for as usual by general practitioners and diabetes/hypertension/NCD nurses. There were no home visits by community nurses/village health volunteers. In district hospital B (intervention), multidisciplinary care teams, community nurses, and village health volunteers were trained on CKD with information on lifestyle modifications and dietary counseling. Educational materials and a protocol checklist were provided in accordance with the Nephrology Society of Thailand and international guidelines on CKD management. 73 , 74 CKD cases were referred by community nurses/village health volunteers during regular home visits to multidisciplinary care teams at the district hospital. The community nurses/village health volunteers also had a checklist on exercise, smoking cessation, avoidance of analgesic/nonsteroidal anti-inflammatory drugs, and avoidance of high salt and protein intake. Two years later, patients with CKD in the intervention group had lower dietary salt and protein intake and lower rates of eGFR decline than did those in the control group. 75 An economic evaluation demonstrated that this program was cost-effective. 76 The conclusions of this study imply that integrated care provided by multidisciplinary care teams at district hospitals in combination with home visits by community nurses/village health volunteers could help delay the progression of CKD through lifestyle modifications, without the intervention of specialists.

In 2015, the Ministry of Public Health announced the prevention of CKD as a national health priority. All referral, provincial, and district hospitals were requested to set up multidisciplinary care teams around CKD. A protocol checklist on the essential parts of CKD management and key performance indicators of CKD were agreed upon. A reference eGFR equation was declared, and the implementation of national serum creatinine standardization is underway.

Our findings illustrate favorable outcomes in a CKD prevention program at a national scale ( Table 5 ). 71 It is yet too early to identify absolute eGFR change over time. We recognize that the key success factors behind our CKD program are the homogeneity of an existing well-organized primary health care system, the inclusion of an integrated care team at district hospitals, frequent home visits by community nurses and village health volunteers in the program, and, most importantly, a strong sense of belonging to their native homeland of the personnel. Our experience shows that in developing countries such as Thailand, combating CKD progression under limited resources is possible, provided that an integrated care program is developed, including trained multidisciplinary care teams, educational materials, protocol checklists, and dedicated community nurses and village health volunteers. This program could be sustainable and cost-effective.

Table 5

Key performance indicators of CKD reportable to the Ministry of Public Health, Thailand

ACEi, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blockade; CKD, chronic kidney disease; eGFR, estimated glomerular filtration rate; HbA 1c , hemoglobin A 1c .

United Arab Emirates (high-income country): early detection of CKD in Abu Dhabi

In 2012, the prevalence of ESKD and CKD in Abu Dhabi were unknown, but the population on dialysis was doubling approximately every 5 years. Of the new patients starting dialysis, 90% started with <90 days of predialysis care, only 2% of patients had a fistula at their first dialysis session, and patients primarily started on HD. There were no systematic attempts at early detection and management of CKD as the projection of future patients with CKD was unknown.

SEHA, the government health system within Abu Dhabi, has a single electronic medical record system that covers the whole country. The data contain patient demographics and information on all patient encounters. Between September 2011 and October 2012, data on 212,314 adults were extracted from the electronic medical record. The eGFR was calculated for every serum creatinine measurement and was used to calculate an estimate of CKD prevalence on the basis of the population breakdown. The prevalence of CKD stage 2 to 5 was estimated to be 22.6% in Emirati men, 12.9% in Emirati women, 26.6% in foreign men, and 16.5% in foreign women.

To address the relative high rates of CKD, extensive discussions occurred at both primary and secondary levels of care; a potential solution was introduced in February 2014. This solution included the adoption of several strategies: the automated calculation of eGFR using the CKD Epidemiology Collaboration 77 equation embedded within the electronic medical record; an automated addition of International Classification of Diseases 9th and 10th Revisions codes for CKD to the electronic medical record based on Kidney Disease: Improving Global Outcomes (KDIGO) CKD 2012 criteria 74 ; an algorithm-based management of CKD; online physician decision support for referral and medication management; physician feedback at the individual, practice, and regional level; and kidney nurses working both at the primary level of care and in multidisciplinary advanced CKD clinics.

At the outset of the program, 35% of patients with CKD stage 3 to 5 managed within primary care and 20% managed within secondary care were taking nonsteroidal anti-inflammatory drugs. From 2011 to 2012, these rates fell to 15% and 10%, respectively. To date, 29,000 patients with CKD have been identified, of whom 25% are at high risk of progression as per the KDIGO classification. 74 More than 3500 patients, however, have had a >30% improvement in eGFR over a 2-year follow-up period. The presentation rate for dialysis with <90 days of predialysis care (emergency start) has fallen from 90% to 35%. The proportion of patients commencing dialysis with an arteriovenous fistula has risen each year, with 34% starting dialysis with a fistula in 2018.

This program of early detection and management of CKD has been extremely successful and continues to improve outcomes for Emirati patients. The program has clearly demonstrated the ability to modify physician prescribing behavior and exemplifies value-based health care with improved patient outcomes at a reduced cost to the health system. Data analysis is ongoing, with more work needed on defining the incidence density of progression to KRT and death as well as hazard ratios of progression and the impact of changes in medication regimen.

HD Strategy Cases

Malaysia (upper-middle-income country): near-universal coverage for dialysis.

Nephrology services in Malaysia have come a long way, from a humble beginning in the 1960s with steady growth to the mid-1970s, when the country was still categorized as an agricultural-based LMIC. With rapid development in the last 2 decades, a full range of nephrology services is now readily available throughout the country at an affordable cost. For an upper-middle-income country, Malaysia has an impressive treatment rate for patients with ESKD.

Action and strategies for HD and PD

How does malaysia achieve near-uhc for dialysis.

Over the last 5 decades, the nephrology community in Malaysia has worked toward achieving the World Health Organization indicators of UHC 78 of dialysis via good stewardship and governance (provided by the government), nephrology champions, key opinion leaders, and professional societies via the following strategies.

Effective stewardship of health reforms

• • Strong support via the MOH by providing sufficient funding for the development, operation, and subsidy of dialysis centers and services throughout the country.
• • Ongoing planning over the last 40 years.
• • Cooperation between private corporations and NGOs to develop more HD centers.

Effective stewardship of public funds

• • Allocation of more funds from the MOH to expand services, particularly in rural areas.
• • Allocation of subsidies to NGOs by the MOH and Treasury.
• • Outsourcing of dialysis to private centers by the Public Service Department, Social Security Organization, and zakat. All of the above agreed to consider dialysis as rehabilitation therapy.
• • Purchasing HD services from all qualified providers.

These measures were a major departure of standard policies of the public sector in the 1970s and 1980s. The funding of dialysis was one of the very first mixed public, private, and NGO financing operations in Malaysia.

Stewardship in proper training of doctors and allied health staff

• • Emphasizing the importance of a proper training program for nephrologists, kidney nurses, and allied head staff, with a syllabus, logbook, and exit evaluation where trainees are assessed by local and external examiners.

Ensuring quality and integrity

• • Introduced quality initiative efforts, such as the development of practice guidelines on KRT and a document on Hemodialysis Quality Standards.
• • Established National Renal Registry (jointly between the MOH and the Malaysian Society of Nephrology) to provide accurate data for health care planners, clinicians, and multinational dialysis industry companies.

Public–private partnership

• • There continues to be collaboration among government, professional societies, private industry, NGOs, and local manufacturers (consumables and solution). There is also widespread implementation of health care laws that have enabled organizations to start an HD facility irrespective of whether they have links to a hospital.

During the last 3 decades of transformation from LMIC to upper-middle-income country, the above measures have resulted in near-universal access to dialysis for all patients with ESKD, at a reasonable cost, with comparable quality to many developed countries.

Malaysia has an interesting dual-tiered system of health care services consisting of a government-led public sector that coexists alongside a private-NGO sector, creating a synergistic public–private/NGO model. The government is the main source of funding for new and existing patients on dialysis (55%–60%); out-of-pocket payments or self-funding for dialysis was ∼26% to 30%; and funding from NGOs remained at 11% to 15% over the years. 78 Public financing, mainly through taxation and/or social health insurance (e.g., Social Security Organization), is the dominant form of financing for dialysis. The majority of patients on HD are treated in the private/NGO sector (54%), but almost all patients on PD are treated in government facilities (97%) via financing operations described above. 79 The total health expenditure in Malaysia was 4.21% of the gross domestic product (RM51,742 million) in 2016 80 ; the total spending on dialysis was US$100 million, accounted for 1.72% of the total health expenditure in 2005. 81

In Malaysia, diabetes and hypertension were the most common causes of ESKD, 82 with the prevalence of 17.5% and 30.3%, respectively, in those older than 18 years. 83 The prevalence of CKD stage 5 was 0.36% in those older than 18 years. 84 Recent forecasting estimates that the cost to treat 51,269 patients on dialysis in the year 2020 will be US$384.5 million. 85 This burden has implications for future health care financing. The prevalence of ESKD is increasing at an alarming rate. Options proposed to tackle this issue include early medical intervention to slow the progression of CKD in high-risk patients, the promotion of kidney transplantation, and the use of more cost-effective dialysis therapies. In Malaysia, kidney failure prevention initiatives have been carried out nationwide, including patient screening in the primary care setting, the prevention of kidney failure workshops targeting primary care doctors and allied health care staff, the development of clinical practice guidelines on CKD management and nephrology services operational policy, and national public awareness of World Kidney Day. Despite kidney transplantation providing the best KRT option, the transplantation rate remains low at 3 pmp owing to a lack of donors, leaving the choice of KRT between HD and PD. 82

In Malaysia, citizens can access the subsidized dialysis services provided by the MOH at university hospitals, Ministry of Defense hospitals, and local authorities. Public sector health care services are considered a national health service with its tax-based financing and heavy subsidies. NGOs and political parties also provide support either by providing services (e.g., dialysis services by the National Kidney Foundation), subsidizing part of the payment, or assisting in the appeal for public donations. These measures combined have resulted in expanded coverage of stand-alone dialysis services over the years ( Figure 4 ), with the number of dialysis centers across Malaysia increasing from 205 in 2000 to 758 in 2014. 79 , 81 , 86

Providing dialysis to meet Malaysian needs. Dialysis treatment by sector (per million population [pmp]), 1980–2016. 79 , 81 , 86 BAKTI, Badan Amal dan Kebajikan Tenaga Isteri-Isteri Menteri dan Timbalan Menteri (Charitable and welfare bodies of the wives of Ministers and deputy Ministers); HD, hemodialysis; JPA, Jabatan Perkhidmatan Awam (Public Service Department) (civil servants and their dependants would be reimbursed by the government); MOH, Ministry of Health, Malaysia (public health care services are funded through general taxation, with annual health budgets allocated by the Ministry of Finance to the MOH); NGO, nongovernmental organization (NGOs are providing support to access dialysis by either providing some of these services [e.g., dialysis services by the National Kidney Foundation {NKF}], subsidizing part of the payment, or assisting in appealing for public donations [e.g., NKF]); SOCSO, Social Security Organization (a government-run social insurance body that receives mandatory contributions from private-sector employees earning below US$950 per month); YKN, Yayasan Kebajikan Negara; Zakat, state-run Islamic social welfare organizations reimburse eligible patients for certain treatments and dialysis, which was included as a rehabilitation therapy.

Between 2005 and 2014, private dialysis centers have almost tripled from 6 to 14 pmp, NGO centers increased from 4 to 5 pmp, and the pmp rate of public centers remained unchanged. Private dialysis centers are distributed mainly in economically developed west coast states of Peninsular Malaysia. The government operates most of the dialysis centers in less developed areas.

Reimbursement by government agencies per HD treatment at private and private for-profit HD centers has not changed since 1999 and remains at about RM120 to RM200 and at RM150 to RM200 per dialysis session, respectively. 81 There were 37,183 patients on dialysis in 2015. 79 In 2015, the incidence and prevalence rates of dialysis were 261 and 1295 pmp, respectively. 82 These rates compare favorably to more developed countries in the region, such as Singapore, South Korea, and Hong Kong. 87

In summary, the number of patients receiving KRT has increased sharply over the last few decades. Malaysia, an upper-middle-income country, has been able to achieve near-UHC for dialysis and consistently reports outcomes; this is usually observed only in industrialized nations. This achievement is due to good stewardship and governance shown by the government, professional societies, NGOs, and clinical champions.

Malawi (low-income country): unique strategy for ESKD care

Malawi, a country of 16.7 million people, has offered free HD services for both AKI and ESKD since 1998. 88 , 89 The first dialysis unit was established in 1998 in Lilongwe with a donation of 4 Gambo AK 95 machines (Baxter International Inc.; Deerfield, IL). As the original HD machines were in poor working order, with spare parts difficult to obtain, patient care was often interrupted and outcomes were generally poor. A second unit was established in Blantyre in 2011 with 4 of the same HD machines to face the increasing demand for services and to reduce the large distances that patients would be required to travel to access dialysis.

All HD machines and water plants were replaced at both units between 2013 and 2014. Lilongwe now has 10 stations and Blantyre has 5. A public–private initiative with Fresenius Medical Care (based in South Africa) has provided 5 additional units; the water plant and dialysis machines were offered at no direct capital cost as part of a 5-year contract to purchase consumables from Fresenius. Training of medical and nursing staff has also been a core component of improved service delivery in Blantyre through the Sister Renal Center Program from the ISN. Dialysis is provided on a twice weekly basis, which has increased the number of patients treated, though at a cost of delivering a lower dialysis dose.

Although HD services have expanded, providing integrated care for kidney disease remains a challenge. Regular adult and pediatric nephrology clinics help identify patients approaching ESKD, but the overwhelming majority of patients present in extremis, requiring emergency dialysis for both AKI and ESKD. Screening patients for CKD in high-risk groups such as those with diabetes, hypertension, and HIV remain challenging because of many reasons including the cost of materials such as urine dipstick and laboratory reagents, a low awareness of kidney disease among the public and medical professionals, and the sheer volume of patients.

There is currently no access to transplantation within Malawi; instead, patients are sent overseas for living donor transplants at a cost of ∼$30,000 borne by either the patient or the government. PD has been delivered when suitable supplies of PD fluid and equipment have been available, but these periods are brief and difficult to sustain. Thus, HD remains, and is likely to remain, the predominant dialysis modality in Malawi. Vascular access for HD also remains a challenge, and surgical expertise is urgently required to address this. Some patients do have a native arteriovenous fistula that was created by either a surgeon in Malawi or visiting specialists, but a regular vascular access service has not formally been established. Complications from both temporary and semipermanent HD catheters are both common and severe.

Significant efforts are being made to provide integrated care for CKD and AKI in Malawi. Both HD units have focused on the development of predialysis nephrology services in terms of clinical activity, teaching, and research. Screening for CKD in high-risk patients such as those with diabetes and HIV has identified an unexpectedly high prevalence of CKD; this further highlights the importance of robust mechanisms for the early detection and management of CKD. 90 , 91 Clinical expertise for nephrology in Malawi remains a significant challenge—the country has just received its first qualified nephrologist. The nursing staff in dialysis units represents an excellent source of clinical expertise and have been instrumental in advancing the delivery of dialysis care and education together with physicians and clinical officers.

Kidney services in Malawi have been supported by bidirectional teaching and training programs with Barts Health NHS Trust in the United Kingdom. This partnership has helped develop clinical, research, and teaching expertise. The volume of patients with kidney disease in Malawi, both acute and chronic, has required the development of a specialist kidney ward to care for patients with both AKI and ESKD at Queen Elizabeth Central Hospital in Blantyre. To address the needs of patients who do not proceed with dialysis, a partnership with palliative care services has been established. This service provides holistic and symptomatic care for patients with ESKD in the absence of dialysis. 92 , 93

Preliminary discussions around providing transplantation in Malawi have identified attendant laboratory, pharmacy, clinical, legal, and ethical challenges; although difficult, they are not impossible to overcome. Although transplantation in Malawi will ultimately lead to a better quality of life for patients and lower direct cost to the government, it remains some years away.

The total number of patients on dialysis in Malawi has dramatically increased with the provision of new equipment, allowing better access to dialysis for both patients with ESKD and those with AKI. 88 Increasing dialysis has saved lives but at a high cost to the health economy, and the HD capacity is not yet sufficient to treat every case of ESKD. Patient dialysis groups in Malawi have become strong and vocal advocates for services for patients with kidney disease and are instrumental in sustaining and improving HD services in conjunction with clinicians. The educational activities undertaken over the last 7 years have strengthened the clinical and research expertise in Malawi. There are significant challenges ahead for kidney care in Malawi, but working with the ISN on the Kidney Care Network project has the potential to make a major impact on the care of AKI, ultimately saving lives. Strengthening the breadth and depth of clinical nephrology expertise sustainably will require continued financial and operational support from the Malawi government and is essential to a national kidney strategy in Malawi.

Kenya (lower-middle-income country): upscaling HD

Kenya, with a population of >50 million, has a huge number of patients with kidney failure and who would potentially benefit from KRT.

HD was first offered in Kenya in 1964 when an HD machine had to be flown in from England along with a team of doctors for a British soldier. In 1970, regular HD was offered in an intensive care unit at the referral hospital, Kenyatta National Hospital (KNH) in the capital Nairobi. PD was introduced in 1971, but this expertise was available only in Nairobi. A kidney unit was established at KNH in 1979, and it remained the only unit in the country until 1982, when private hospitals started offering both HD and PD. As these units were located only in Nairobi, other regions still had no access to HD and anybody who needed dialysis traveled to the capital city. By 1990, most provincial hospitals had the personnel to provide acute PD and a few patients started on continuous ambulatory PD. With the introduction of the double bag system in 2002, PD slowly became costlier than HD and few patients opted for this modality. Starting in 2002, satellite HD units appeared outside Nairobi; by 2006, however, there were still only 4 government hospitals offering HD across the country.

In 1978, the first ever kidney transplantation was carried out in a patient whose horseshoe kidneys had been mistaken for an abdominal mass and inadvertently removed; she lived for 1 year after surgery. A few private hospitals started kidney transplantation in 1984, though the numbers were low and irregular. By 1988, KNH was also doing kidney transplantation; however, over the next 20 years, only 130 had been done.

In 2010, it became clear that the government could no longer cope with the growing burden of ESKD and the Kenya Renal Association drafted a plan to increase kidney services ( Table 6 94 , 95 , 96 , 97 , 98 , 99 ).

Table 6

Progress of kidney services in Kenya since 1995

Actions and strategies for CKD/ESKD care

A partnership between KNH and Novartis Pharmaceuticals was established in 2010 to retrain the transplantation team at KNH. Over the next few years, with travel between Spain and Kenya, the team was fully equipped to run a successful transplantation program. The number of transplantations increased, and expertise was shared with some of the private hospitals.

Because of lobbying from powerful dialysis patient groups to improve the situation in the country, the government implemented the Kenya Renal Association recommendations to increase kidney services in 2015. Recommendations that were implemented included the establishment of at least 1 HD unit in each of the 47 counties with 5 machines each over a 2-year period. This task involved the government creating new structures in regions that did not have the necessary infrastructure. Currently, 90% of the county units, representing 40% of dialysis units in the country, are in place and delivering services to patients.

The National Hospital Insurance Fund, established in 1966, provides UHC to all Kenyans 18 years or older and who have a monthly income of >US$10; monthly contributions range from US$5 to US$17. The National Hospital Insurance Fund has the aim of ensuring access to affordable, sustainable, equitable, and quality care and was entrusted by the government to provide funds to reimburse dialysis centers.

Kenya has been entrusted with the East African Kidney Institute of Urology, Nephrology, and Transplantation as part of a new initiative set up by the African Development Bank. The overall objective of this institute is to develop a world class institution that facilitates the realization of the vision to strengthen health training, research capacity, and provision of services to the local and international communities, more so in the East and Central African regions. Although a full nephrology fellowship program is 2 years in length, to address the urgent need for trained doctors, the institute created a 3-month preceptorship.

Despite the advancements in infrastructure, many challenges remain ( Table 7 ). A good supportive structure is needed to ensure the success of the program. Involving partners such as the World Health Organization, United Nations, and ISN to support the program and endorse safety is important. Adapting good guidelines that suit the patient needs is critical.

Table 7

Challenges for the growing kidney replacement therapy program in Kenya

BMD, bone mineral density; PD, peritoneal dialysis.

The MOH is charged with implementing this program and to ensure standards are met by empowering the medical board. Funding comes from the National Hospital Insurance Fund, and the supply of medicines comes from the Kenya Medical Supplies Authority, a state corporation whose mandate is to procure, warehouse, and distribute drugs and medical supplies for prescribed public health programs.

In 2017, a health bill was passed into law, which enables public hospitals in Kenya to start deceased donor (DD) kidney transplantation. Once implemented, this law will ease the number of patients waiting for a kidney transplantation. The Kenya Renal Association, which oversees the program, has started creating a registry for dialysis and transplantation. Nephrologists work closely with the MOH to ensure standards for safe HD are met by each unit. A national epidemiological survey to determine the number of patients with kidney disease in Kenya is being planned. Despite all these systems being put into place, further team efforts are required to ensure success.

PD Strategy Cases

South africa (upper-middle-income country): pediatric pd for eskd.

ESKD in pediatric patients is a significant problem in South Africa as it is in many parts of the world. Adults often get preference in terms of dialysis and transplantation.

Facilities are present in 3 of the larger academic centers—Johannesburg, Durban, and Cape Town—to provide KRT and transplantation to children who have access to these centers. There is lobbying at the local hospital level for the purchase of pediatric and, in some centers, infant dialysis equipment. Provision for pediatric facilities has also been facilitated in some private facilities. There has been some lobbying at the government level for specific pediatric support but with limited success.

Like adult centers in South Africa, pediatric centers do not provide chronic dialysis for children unless they are suitable for transplantation. This has proved difficult as many children have started on acute dialysis, only to be changed to conservative care as their family and home facilities are not suitable for long-term dialysis. This transition plan has been difficult for some centers, and thus long-term dialysis has been started in some children without a satisfactory plan for future dialysis.

The first strategy in developing a pediatric dialysis program in South Africa is to create pediatric programs where adult programs exist. Adult programs can then provide the initial knowledge and technical support associated with caring for adolescents and bigger children.

The next strategy is to use a PD-First approach for children who have been accepted for transplantation and thus dialysis. This uses automated home cycle machines for overnight dialysis while children are sleeping, enabling them to continue school during the day. Families are trained during an in-patient visit over a period of 2 weeks and then examined on their technique before discharge. In most centers, a single home visit is done to see if this is a suitable option as well as to advise them in practical matters of having a dialysis machine at home. There are currently 2 marketed machines for home automated PD in children: Homechoice Claria by Baxter International Inc. and Sleepsafe by Fresenius Medical Care (Waltham, MA).

Advanced technology (Claria Baxter) now allows the remote daily follow-up of overnight dialysis patterns.

Other strategies include the training and employment of specialized advanced nurse practitioners who can operate in- and outpatient PD programs.

Children who have failed PD and would go onto HD provide the challenge to appropriate pediatric and infant HD lines and filters. While pediatric centers are being established, bigger children will often initially dialyze in adult facilities. This emphasizes the need for training of medical and nursing staff in both adult and pediatric centers.

The ultimate goal in pediatrics is to arrange kidney transplantation as soon as possible; this avoids stunting due to long-term dialysis. To ensure the success of a pediatric transplantation program, it is critical to have a few dedicated centralized areas across the country. This will centralize the skills base and improve results.

Over the last 10 years, pediatric nephrology has grown in South Africa from 10 to 27 active pediatric nephrologists. Over the last 15 years, at the Red Cross Children’s Hospital alone, we have trained a further 24 pediatric nephrologists from elsewhere in Africa.

The challenge remains to increase the training of nurses, technicians, and advanced nurse practitioners to provide dialysis and transplantation for children.

Overall, the situation is slowly improving: in December 2016, the South African Renal Registry found that there were 54, 53, and 86 patients younger than 19 years on PD and HD, and with a functioning transplanted kidney, respectively (with permission from Razeen Davids, Webmaster of South African Renal Registry). The result of staff training as well as collaboration with adult nephrology teams gives hope for the future of pediatric patients with nephrology disorders in South Africa as well as in other parts of Africa.

Transplantation Strategy Cases

South korea (high-income country): system development for dd kidney transplantation.

Kidney transplantation improves the quality of life of patients with ESKD and is cost-effective. The first living-donor kidney transplantation in Korea was conducted in 1969, and the first DD kidney transplantation was conducted in 1976. The number of hospitals performing kidney transplantation has since rapidly increased. However, as most kidneys are donated within families and there is an increasing trend of smaller families, living donor kidney donation has stagnated. Furthermore, the revered traditional Confucian view teaches that your entire body was given to you by your parents and people are taught to value their bodies. The meaning of this teaching has been overinterpreted to mean value all parts of human body even after death , resulting in the rejection of organ procurement from DDs.

To address the shortage, in 1988, the Korean Society for Transplantation proposed DD organ transplantation legislation to the congress. Although DD kidney transplantation was being conducted by several hospitals at the time, it took 10 years to secure legal support for it. This situation resulted in kidneys from the poor being traded on the black market. Thus, a renewed legal review of brain death was initiated, and the Organ Transplantation Law was passed in 1999 and the Korean Network for Organ Sharing was established in 2000. The major role of the Korean Network for Organ Sharing was to review the legal and ethical relationship between living donors and their recipients. It also became responsible for the management of the transplantation wait-list and the allocation of DDs. Over time, the Korean Network for Organ Sharing became a national authority, regulating organ transplantation–related activities.

The overly tight regulation of each process soon resulted in a decline in kidney transplantation, and the annual number of patients who died while waiting for organ transplantation increased. Patients became increasingly desperate, and overseas transplantation rapidly increased starting in 2002. The Organ Allocation Study Group, under the Korean Society for Transplantation, elected to change its name to the Deceased Organ Donation Improvement Program Committee in 2009 and started devoting its efforts to formulating strategic plans for reactivating DD organ transplantation. The Organ Allocation Study Group cooperated with the congress in revising the existing law in 2010, adding a law on mandatory reporting, the establishment of an independent organ procurement organization, and the implementation of a transplantation registry.

Vitallink is an NGO that was established by the Korean Society for Transplantation in August 2009 to promote public awareness of DD organ donation. Vitallink educates medical and high school students about organ donation. Vitallink also established the Korean Organ Donation Network in 2010 to conduct consistent education for NGO leaders. They jointly collaborate with Catholic and Buddhist NGOs to host various campaigns. Finally, Vitallink has been supporting the development of the Asian organ transplantation program through annual workshops and the provision of training courses for medical professionals from Korea and abroad.

The Korea Organ Donation Agency was established in 2009. Currently, this agency has jurisdiction over 3 regional divisions. The main responsibility of procurement coordinators is to discover potential DDs by visiting hospitals. When the Korea Organ Donation Agency receives notification of a potential brain death donor, they first visit the hospital to conduct a primary medical evaluation for donor eligibility and then obtain consent from the family, process the evaluation of brain death, and contact and coordinate the organ procurement teams and operations. After donation, they collect the body to transfer to the family and provide emotional support. The Korea Organ Donation Agency is also in charge of education for medical professionals and donor families.

In 2014, the Korean Society for Transplantation established a web-based registry, the Korean Organ Transplantation Registry. The Korean Organ Transplantation Registry collects data on ∼85% of all organ transplantation and issues an annual report. They have hosted various seminars and provide research grants and awards. The Korean Organ Transplantation Registry has now started the Asian Organ Transplantation Registry (ASTREG).

The rate of DD organ transplantation in Korea has greatly increased because of the adoption of new strategies ( Figure 5 ). 100 This increase has led to a decrease in the number of overseas transplantation ( Figure 6 ). 100 As of 2017, the number of DD organ donations in Korea was 10.7 pmp, the highest in Asia; however, Korea is still ranked only 37th worldwide. To provide a better life for patients with ESKD in Korea, partnerships will be required with other Asian countries in organ transplantation.

Number of kidney transplantation cases in South Korea. Data from Ahn HJ, Kim HW, Han M, et al. Changing patterns of foreigner transplants in Korea and overseas organ transplants among Koreans. Transplantation. 2018;102:310–317. 100 Copyright © 2018 Wolters Kluwer Health, Inc.

Relationship between the number of overseas organ transplantation cases and the number of deceased organ donors in South Korea. Doha: Doha, Qatar; DOI, Declaration of Istanbul; IOPO, independent organ procurement organization; KODA, Korea Organ Donation Agency; KOTRY, Korean Organ Transplantation Registry. Reproduced with permission from Ahn HJ, Kim HW, Han M, et al. Changing patterns of foreigner transplants in Korea and overseas organ transplants among Koreans. Transplantation. 2018;102:310–317. 100 Copyright © 2018 Wolters Kluwer Health, Inc.

Ghana (lower-middle-income country): framework for the development of living donor kidney donation

In 2008, a living donor kidney transplantation program was established in Ghana in collaboration with the Transplant Links Community and the Queen Elizabeth Hospital Birmingham, part of University Hospitals Birmingham NHS Foundation Trust–ISN Sister Renal Center. Our model for developing a kidney transplant program involved 3 stages ( Figure 7 ): the pre-transplant stage, crucial in ensuring effective planning and long-term sustainability; and the transplant and post-transplant stages, important for clinical capacity building, patient care, monitoring, and evaluation, which then feed back into the pre-transplant stage to optimize the transplantation process.

Model for kidney transplantation in Ghana. HDU, high-dependency unit; ICU, intensive care unit.

Pre-transplant planning

The decision to undertake living donor kidney donation was based on the youthfulness of patients on dialysis, the cost of HD (beyond the means of most patients), and the opportunity for an improved quality of life. First, a knowledgeable and committed champion was identified to lead, drive, and coordinate the program through effective and ongoing engagement with all stakeholders. 101

The second step involved an assessment of the capacity of the hospital to ensure that it could support kidney transplantation. A checklist was developed to assess infrastructure : personnel, policies, protocols, laboratory support, and medicine availability. This was implemented by a team including heads of departments of medicine, surgery, pharmacy, pathology, and anesthesia. The assessment of clinical capacity included identification of comprehensive protocols for both donor and recipient work-up and immunosuppressant management, including a choice of affordable generic immunosuppressants. Identified key gaps included no legal framework for organ transplantation, a lack of transplantation surgeons, and the nonavailability of protocols and some immunosuppressive drugs.

The third step was the development of a legal and ethical framework for living donor kidney donation. In the absence of a national legal framework for transplantation, hospital management and the MOH decided to adopt the Declaration of Istanbul on organ trafficking and transplant tourism as a means of ensuring best practices. 102 , 103 To work within the principles of the Declaration of Istanbul, only living-related donors were considered. In addition, a transplant ethics committee was established, guided by the UK Human Tissue Act (2004), the World Health Organization Guiding Principles on Human Cell, Tissue and Organ Transplantation, and the Declaration of Istanbul, to independently assess the transplantation process and to avoid coercion and organ trafficking. 104 , 105 , 106 The committee comprised a retired professor of surgery, a priest, a lawyer, a clinical psychologist, and a professor in public health.

The final step was financing . Given the projected costs of a transplantation program, the hospital engaged funders including the National Health Insurance Scheme and the Social Security and National Insurance Trust. The hospital also provided letters to patients to solicit funds for transplantation. The Transplant Links Community raised enough funds to cover the costs of the visiting transplantation team, volunteers who visited during their holidays. The National Kidney Foundation–Ghana raised funds to support medicines and laboratory investigations. The cost of a kidney transplantation was estimated at US$10,000 per transplantation, including pre- and post-transplantation laboratory investigations, hospital admission, both operations (donor and recipient), postoperative management, and a 3-month supply of immunosuppressive drugs. Corporate organizations sponsored transplantation patients to ensure that all patients, even those who could not afford it, were provided for, including ongoing immunosuppressants, which average US$3600 to US$4000 per year.

• (i) Development of local clinical capacity for transplantation : A multidisciplinary clinical team made up of local nephrologists, urologists, anesthetists, clinical pharmacists, and critical care nurses was created. Clinical expertise in kidney transplantation was achieved with periods of training of surgeons and physicians in South Africa and the United Kingdom through ISN fellowship awards.
• (ii) Donor and recipient selection: Recipients along with suitable living donors were selected from dialysis centers. Two local nephrologists applied standard guidelines to evaluate donor and recipient pairs. Donors and recipients were provided with counseling and educational materials on the risks and alternatives available. Materials were provided in English; however, a team of local nurses were able to counsel in the local language. After the medical evaluation, donors and recipients were further evaluated by the transplantation surgeon and the anesthetist. The ethics committee provided an independent assessment and interviewed each pair separately and together. Once the committee was satisfied that the pair were genuinely related, that the donor was not acting under any coercion, and that the Declaration of Istanbul was adhered to, written approval was given to proceed to the transplant stage. Two other nephrologists from the international team reevaluated the donor-recipient pair before surgery.
• (iii) Transplantation procedure and follow-up: The University Hospitals Birmingham NHS Foundation Trust and Transplant Links Community teams made 2 initial visits before the first transplantation and then performed the kidney transplantations on subsequent visits. These visits enabled hands-on training of local surgeons, anesthetists, nurses, and theater technicians. The Ghanaian team adopted the University Hospitals Birmingham NHS Foundation Trust protocols, with minor modifications, for patient management and follow-up pre-, intra-, and postoperation.
• (iv) Monitoring and evaluation of the program involved entering all patients into a database for ongoing follow-up: After the first set of kidney transplantations done in 2008, the donor work-up process was reevaluated and a new donor work-up sheet was designed to reduce the cost of the donor work-up ( Appendix 2 ). Outcome of the transplantation program has been good: in the first 17 transplantations done, there was 100% 1-year patient survival and 91.7% graft survival. 106

ESKD is a global problem and cuts across all sociodemographic differences and cultural context. Despite the diversity in countries discussed here, common themes emerged in the approach to reducing the burden of CKD/ESKD:

• • the importance of screening high-risk populations and multidisciplinary care in slowing the rate of progression of CKD;
• • improving access to KRT options (HD, PD, DD, and living donor transplantation) to all patients (including rural) affected by ESKD;
• • moving toward financially sustainable KRT options; and
• • the recognition of the harm of nephrotoxic drugs.

Countries have made great strides to date in recognizing the importance of and developing strategies to address CKD/ESKD across different income status ( Table 8 ). Future work needs to continue to rely on strong data collection and analysis to identify key risk factors across populations, enact strategies that delay the onset and progression of CKD, increase universal access to appropriate KRT, and use the leverage of international collaboration to strengthen systems around the world ( Figure 8 ). Capitalizing on partnerships that can limit the financial burden on LMIC should continue to be explored. A cohesive collaborative approach among experts around the globe will continue to strengthen the international nephrology community and improve outcomes for patients with CKD/ESKD.

Table 8

Featured strategies of CKD/ESKD care stratified by World Bank economic classification

CKD, chronic kidney disease; ESKD, end-stage kidney disease; KRT, kidney replacement therapy; NGO, nongovernmental organization; NSAID, nonsteroidal anti-inflammatory drug; UHC, universal health coverage.

Strengths, weaknesses, opportunities, and threats (SWOT) analysis of chronic kidney disease (CKD)/end-stage kidney disease (ESKD) strategies .

Publication of this article was supported by the International Society of Nephrology.

DCHH reports grant support from the National Health and Medical Research Council. GGG reports grant support from CloudCath and ICON Clinical Research, Ltd. BLG reports lecture fees from Baxter, Fresenius Medical Care, Sanofi, and Kwoya Kirin and grant support from Baxter and Kwoya Kirin. JD reports consulting fees from the International Society of Nephrology. All the other authors declared no competing interests.

Acknowledgments

This article emerged as an individual product of the International Society of Nephrology’s 2nd Global Kidney Health Summit held in Sharjah, United Arab Emirates, in March 2018 and portions of the material in this document have been published in the full report from the summit (Harris DCH, Davies SJ, Finkelstein FO, et al. Increasing access to integrated ESKD care as part of universal health coverage. Kidney Int. 2019;95:S1–S33 1 ). In addition to the International Society of Nephrology, support of the summit was provided through unrestricted grants from Baxter and B. Braun.

MT was supported by the David Freeze Chair in Health Services Research at the University of Calgary. The Libin Institute at the University of Calgary is the host institution for the Pan American Health Organization/World Health Organization’s Coordinating Centre in Prevention and Control of Chronic Kidney Disease.

The authors thank Drs. Hong Teck Chua, Chwee Choon Tan, and Zaki Morad for assisting with the preparation of the section on Malaysia and Dr. Shang-Jyh Hwang for the section on Taiwan. The authors thank the patients; the donors; Mr. Charles Antwi; Professor Nii Otu Nartey, former Chief Executive Officer of the Korle Bu Teaching Hospital; and the doctors; especially Dr. Dwomoa Adu, Dr. Bernard Morton, Professor Michael Mate Kole, Mr. Andrew Ready; and the Transplant Links Community team who worked together to make transplantation possible in Ghana. The authors also thank Dr. Manar Bushra, Director of the Sudan National Center for Kidney Diseases and Surgery, for the statistics provided.

The views expressed in this commentary are solely the responsibility of the authors and they do not necessarily reflect the views, decisions, or policies of the institutions with which they are affiliated.

Appendix 1 │ Evolutionary pathway of CKD/ESKD integrated care in Taiwan

BNHI, Bureau of National Health Insurance; CKD, chronic kidney disease; DOH, Department of Health; eGFR, estimated glomerular filtration rate; ERA-EDTA, European Renal Association – European Dialysis and Transplant Association; ESKD, end-stage kidney disease; NBHP, National Bureau of Health Promotion; NGO, nongovernmental organization; NHI, National Health Insurance; PD, peritoneal dialysis; TSN, Taiwan Society of Nephrology; USRDS, United States Renal Data System.

Appendix 2 │ Work-up checklist for living donor kidney donation in Ghana

• Collections
• Chronic Kidney Disease Case Presentation PPT

Chronic Kidney Disease Case Presentation PPT & Google Slides

Best Chronic Kidney Slides For Presentation

About this template , feature of this template .

• Parts Of The Body
• Chronic Kidney Disease Case
• Kidney Disease Case
• Chronic Kidney Disease
• Kidney Disease
• Kidney Disease Report
• Kidney Structure
• Kidney Anatomy
• Google Slides

685+ Templates

124+ Templates

Science & Research

182+ Templates

Telemedicine

40+ Templates

333+ Templates

86+ Templates

116+ Templates

44+ Templates

46+ Templates

191+ Templates

You May Also Like These PowerPoint Templates

An official website of the United States government

The .gov means it’s official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

The site is secure. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

• Publications
• Account settings
• My Bibliography
• Collections
• Citation manager

Save citation to file

Email citation, add to collections.

• Create a new collection
• Add to an existing collection

Add to My Bibliography

Your saved search, create a file for external citation management software, your rss feed.

• Search in PubMed
• Search in NLM Catalog
• Add to Search

Global case studies for chronic kidney disease/end-stage kidney disease care

Affiliations.

• 1 Kidney Research Center, Department of Nephrology, Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Taoyuan, Taiwan.
• 2 Centre for Transplantation and Renal Research, Westmead Institute for Medical Research, University of Sydney, Sydney, New South Wales, Australia.
• 3 Institute of Biomedical Ethics and the History of Medicine, University of Zurich, Zurich, Switzerland.
• 4 Renal Division, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
• 5 Division of Nephrology, The University of Tokyo School of Medicine, Hongo, Japan.
• 6 State Key Laboratory of Organ Failure Research, National Clinical Research Center for Kidney Disease, Division of Nephrology, Nanfang Hospital, Southern Medical University, Guangzhou, China.
• 7 Servicio de Nefrologia, Hospital Civil de Guadalajara Fray Antonio Alcalde, University of Guadalajara Health Sciences Center, Hospital 278, Guadalajara, Jalisco, Mexico.
• 8 Almughtaribeen University, Khartoum, Sudan.
• 9 Department of Nephrology, Dalal Jamm Hospital, Cheikh Anta Diop University Teaching Hospital, Dakar, Senegal.
• 10 Dialysis Unit, CASMU-IAMPP, Montevideo, Uruguay.
• 11 Division of Nephrology, Department of Internal Medicine, Rajavithi Hospital, Bangkok, Thailand.
• 12 Department of Medicine, Chulalongkorn Hospital, Bangkok, Thailand.
• 13 Division of Nephrology, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.
• 14 Bhumirajanagarindra Kidney Institute, Bangkok, Thailand.
• 15 SEHA Dialysis Services, Abu Dhabi, United Arab Emirates.
• 16 Department of Nephrology and Clinical Research Centre, Hospital Serdang, Jalan Puchong, Kajang, Selangor, Malaysia.
• 17 Department of Nephrology, Barts Health NHS Trust, London, UK.
• 18 Centre for Nephrology, University College London, London, UK.
• 19 Malawi Ministry of Health, Queen Elizabeth Central Hospital, Blantyre, Malawi.
• 20 Parklands Kidney Centre, Nairobi, Kenya.
• 21 Department of Medicine, The Aga Khan University Hospital, Nairobi, Kenya.
• 22 Paediatric Intensive and Critical Unit, Red Cross War Memorial Children's Hospital, University of Cape Town, Cape Town, South Africa.
• 23 Division of Nephrology, College of Medicine, Seoul National University, Seoul, Korea.
• 24 School of Medicine and Dentistry, College of Health Sciences, University of Ghana, Legon, Accra, Ghana.
• 25 Department of Medicine, University of Calgary, Calgary, Alberta, Canada.
• 26 Pan American Health Organization/World Health Organization's Coordinating Centre in Prevention and Control of Chronic Kidney Disease, University of Calgary, Calgary, Alberta, Canada.
• 27 International Society of Nephrology, Brussels, Belgium.
• PMID: 32149007
• PMCID: PMC7031689
• DOI: 10.1016/j.kisu.2019.11.010

The prevalence of chronic kidney disease and its risk factors is increasing worldwide, and the rapid rise in global need for end-stage kidney disease care is a major challenge for health systems, particularly in low- and middle-income countries. Countries are responding to the challenge of end-stage kidney disease in different ways, with variable provision of the components of a kidney care strategy, including effective prevention, detection, conservative care, kidney transplantation, and an appropriate mix of dialysis modalities. This collection of case studies is from 15 countries from around the world and offers valuable learning examples from a variety of contexts. The variability in approaches may be explained by country differences in burden of disease, available human or financial resources, income status, and cost structures. In addition, cultural considerations, political context, and competing interests from other stakeholders must be considered. Although the approaches taken have often varied substantially, a common theme is the potential benefits of multistakeholder engagement aimed at improving the availability and scope of integrated kidney care.

Keywords: chronic kidney disease; dialysis; end-stage kidney disease; transplantation.

© 2020 International Society of Nephrology. Published by Elsevier Inc. All rights reserved.

PubMed Disclaimer

• The second Global Kidney Health Summit outputs: developing a strategic plan to increase access to integrated end-stage kidney disease care worldwide. Harris DCH, Davies SJ, Finkelstein FO, Jha V. Harris DCH, et al. Kidney Int Suppl (2011). 2020 Mar;10(1):e1-e2. doi: 10.1016/j.kisu.2019.09.001. Epub 2020 Feb 19. Kidney Int Suppl (2011). 2020. PMID: 32154795 Free PMC article. No abstract available.

Similar articles

• Tuberculosis. Bloom BR, Atun R, Cohen T, Dye C, Fraser H, Gomez GB, Knight G, Murray M, Nardell E, Rubin E, Salomon J, Vassall A, Volchenkov G, White R, Wilson D, Yadav P. Bloom BR, et al. In: Holmes KK, Bertozzi S, Bloom BR, Jha P, editors. Major Infectious Diseases. 3rd edition. Washington (DC): The International Bank for Reconstruction and Development / The World Bank; 2017 Nov 3. Chapter 11. In: Holmes KK, Bertozzi S, Bloom BR, Jha P, editors. Major Infectious Diseases. 3rd edition. Washington (DC): The International Bank for Reconstruction and Development / The World Bank; 2017 Nov 3. Chapter 11. PMID: 30212088 Free Books & Documents. Review.
• An update on the global disparities in kidney disease burden and care across world countries and regions. Bello AK, Okpechi IG, Levin A, Ye F, Damster S, Arruebo S, Donner JA, Caskey FJ, Cho Y, Davids MR, Davison SN, Htay H, Jha V, Lalji R, Malik C, Nangaku M, See E, Sozio SM, Tonelli M, Wainstein M, Yeung EK, Johnson DW; ISN-GKHA Group. Bello AK, et al. Lancet Glob Health. 2024 Mar;12(3):e382-e395. doi: 10.1016/S2214-109X(23)00570-3. Lancet Glob Health. 2024. PMID: 38365413 Review.
• Status of care for end stage kidney disease in countries and regions worldwide: international cross sectional survey. Bello AK, Levin A, Lunney M, Osman MA, Ye F, Ashuntantang GE, Bellorin-Font E, Benghanem Gharbi M, Davison SN, Ghnaimat M, Harden P, Htay H, Jha V, Kalantar-Zadeh K, Kerr PG, Klarenbach S, Kovesdy CP, Luyckx VA, Neuen BL, O'Donoghue D, Ossareh S, Perl J, Rashid HU, Rondeau E, See E, Saad S, Sola L, Tchokhonelidze I, Tesar V, Tungsanga K, Turan Kazancioglu R, Wang AY, Wiebe N, Yang CW, Zemchenkov A, Zhao MH, Jager KJ, Caskey F, Perkovic V, Jindal KK, Okpechi IG, Tonelli M, Feehally J, Harris DC, Johnson DW. Bello AK, et al. BMJ. 2019 Oct 31;367:l5873. doi: 10.1136/bmj.l5873. BMJ. 2019. PMID: 31672760
• Current status of health systems financing and oversight for end-stage kidney disease care: a cross-sectional global survey. Yeung E, Bello AK, Levin A, Lunney M, Osman MA, Ye F, Ashuntantang G, Bellorin-Font E, Benghanem Gharbi M, Davison S, Ghnaimat M, Harden P, Jha V, Kalantar-Zadeh K, Kerr P, Klarenbach S, Kovesdy C, Luyckx V, Neuen B, O'Donoghue D, Ossareh S, Perl J, Ur Rashid H, Rondeau E, See E, Saad S, Sola L, Tchokhonelidze I, Tesar V, Tungsanga K, Turan Kazancioglu R, Wang AY, Wiebe N, Yang CW, Zemchenkov A, Zhao M, Jager KJ, Caskey F, Perkovic V, Jindal K, Okpechi IG, Tonelli M, Feehally J, Harris DC, Johnson D. Yeung E, et al. BMJ Open. 2021 Jul 9;11(7):e047245. doi: 10.1136/bmjopen-2020-047245. BMJ Open. 2021. PMID: 34244267 Free PMC article.
• Global Epidemiology of End-Stage Kidney Disease and Disparities in Kidney Replacement Therapy. Thurlow JS, Joshi M, Yan G, Norris KC, Agodoa LY, Yuan CM, Nee R. Thurlow JS, et al. Am J Nephrol. 2021;52(2):98-107. doi: 10.1159/000514550. Epub 2021 Mar 22. Am J Nephrol. 2021. PMID: 33752206 Free PMC article. Review.
• Factors related to the disaster preparedness of patients on haemodialysis from Sichuan, China, during COVID-19: A cross-sectional study. Zhu L, Liu Y, Li S, Liao R, Fu P, Yuan H. Zhu L, et al. Nurs Open. 2024 Aug;11(8):e70005. doi: 10.1002/nop2.70005. Nurs Open. 2024. PMID: 39180141 Free PMC article.
• Prevalence and predictors of long-term progression of chronic kidney disease in people with HIV in Ghana from 2003-2018. Chadwick DR, Barker F, Smith C, Perditer O, Hardy Y, Owusu D, Villa G, Sarfo FS, Geretti AM, Phillips R. Chadwick DR, et al. BMC Nephrol. 2024 Jul 29;25(1):241. doi: 10.1186/s12882-024-03537-7. BMC Nephrol. 2024. PMID: 39075393 Free PMC article.
• The Future of Kidney Care in Low- and Middle-Income Countries: Challenges, Triumphs, and Opportunities. Kalyesubula R, Aklilu AM, Calice-Silva V, Kumar V, Kansiime G. Kalyesubula R, et al. Kidney360. 2024 Jul 1;5(7):1047-1061. doi: 10.34067/KID.0000000000000489. Epub 2024 Jun 26. Kidney360. 2024. PMID: 38922683 Free PMC article. Review.
• Development of a multiple convolutional neural network-facilitated diagnostic screening program for immunofluorescence images of IgA nephropathy and idiopathic membranous nephropathy. Xia P, Lv Z, Wen Y, Zhang B, Zhao X, Zhang B, Wang Y, Cui H, Wang C, Zheng H, Qin Y, Sun L, Ye N, Cheng H, Yao L, Zhou H, Zhen J, Hu Z, Zhu W, Zhang F, Li X, Ren F, Chen L. Xia P, et al. Clin Kidney J. 2023 Jul 18;16(12):2503-2513. doi: 10.1093/ckj/sfad153. eCollection 2023 Dec. Clin Kidney J. 2023. PMID: 38046020 Free PMC article.
• Disease Burden and Epidemiological Trends of Chronic Kidney Disease at the Global, Regional, National Levels from 1990 to 2019. Ying M, Shao X, Qin H, Yin P, Lin Y, Wu J, Ren J, Zheng Y. Ying M, et al. Nephron. 2024;148(2):113-123. doi: 10.1159/000534071. Epub 2023 Sep 15. Nephron. 2024. PMID: 37717572 Free PMC article.
• Harris D.C.H., Davies S.J., Finkelstein F.O. Increasing access to integrated ESKD care as part of universal health coverage. Kidney Int. 2019;95:S1–S33. - PubMed
• World Bank Data Team New country classifications by income level: 2019-2020. http://blogs.worldbank.org/opendata/new-country-classifications-income-l... Available at:
• Wen C.P., Cheng T.Y., Tsai M.K. All-cause mortality attributable to chronic kidney disease: a prospective cohort study based on 462 293 adults in Taiwan. Lancet. 2008;371:2173–2182. - PubMed
• Hwang S.J., Tsai J.C., Chen H.C. Epidemiology, impact and preventive care of chronic kidney disease in Taiwan. Nephrology (Carlton.) 2010;15(suppl 2):3–9. - PubMed
• Lin M.Y., Cheng L.J., Chiu Y.W. Effect of national pre-ESRD care program on expenditures and mortality in incident dialysis patients: a population-based study. PLoS One. 2018;13 - PMC - PubMed

Publication types

• Search in MeSH

Related information

• Cited in Books

LinkOut - more resources

Full text sources.

• Elsevier Science
• Europe PubMed Central
• PubMed Central

• Citation Manager

NCBI Literature Resources

MeSH PMC Bookshelf Disclaimer

The PubMed wordmark and PubMed logo are registered trademarks of the U.S. Department of Health and Human Services (HHS). Unauthorized use of these marks is strictly prohibited.